>>WELCOME TO THE 143 RD
NATIONAL ADVISORY COUNCIL ON THE
DRUG ABUSE AND IT'S REQUIRED AS
MANY ADVISORY MEETINGS AS
POSSIBLE BE OPEN TO THE PUBLIC.
THIS INCLUDES MEETINGS OF THE
NATIONAL ADVISORY COUNCIL AND
DRUG ABUSE.
TODAY'S MEETING IS OPEN TO THE
PUBLIC AND BEING VIDEOCAST AND
RECORDED.
MINUTES OF THE MEETING WILL BE
AVAILABLE ON THE NIDA HOME PAGE
IN ACCORDANCE WITH THE OPEN
COUNCIL MEETING POSTED ON THE
NIH VIDEOCAST SITE.
MEMBERS OF THE PUBLIC WHO WISH
TO EXPRESS VIEWS REGARDING ANY
ITEMS DISCUSSED DURING THE
MEETING MAY WRITE SUSAN WEISS
THE EXECUTIVE SECRETARY WITHIN
10 DAYS OF THE MEETING.
ANY LETTERS FROM THE PUBLIC WILL
RECEIVE CAREFUL CORRECTIONS.
ARE THERE AMENDMENTS OR
CORRECTIONS TO THE MEETING OF
THE SEPTEMBER COUNCIL MEETING
THAT FOR WHICH YOU HAVE IN YOUR
ELECTRONIC COUNCIL BOOKS?
UNDER THE NIDA CURRENT COUNCIL.
MOTION TO APPROVE THE MINUTES?
REICH SECOND?
EVERYONE IN FAVOR?
ANY ABSTAINING?
IF NOT I'LL GIVE YOU THE FUTURE
COUNCIL DATES ANNOUNCING.
THE NEXT ONE IS GOING TO BE MAY
9 AND MAY 10 THIS YEAR JOINTLY
WITH THE NCI AND SEPTEMBER 12
WE'LL HAVE THE THIRD COUNCIL
MEETING FOR 2023.
AT THIS POINT I'M GOING TO
INTRODUCE FOUR NEW MEMBERS FOR
COUNCIL AND WANT TO WELCOME THEM
AND WILL BE READING A SUCCINCT
SUMMARY AND REPRESENT A DIVERSE
SET OF EXPERTISE AND
EXPERIENCES.
SHE RECEIVED HER DOCTORATE FROM
VIRGINIA COMMONWEALTH
UNIVERSITY.
SINCE GRADUATED SHE HAS DONE
RESEARCH FOCUSSING AND
UNDERSTANDING HOW GENETIC AND
ENVIRONMENTAL FACTORS WORK
TOGETHER TO SHAPE SUBSTANCE USE
BEHAVIORS AND THEIR
RELATIONSHIPS WITH OTHER MENTAL
AND PHYSICAL OUTCOMES.
WHILE EPIDEMIOLOGICAL TOOLS ARE
KEY TO HER RESEARCH SHE ENGAGES
IN TRANSLATIONAL IMAGING AND
MULTIOMIC AND DATA.
THE SECOND COUNCIL IS DR
DR. DR. DUVERNAY AND PREVIOUSLY
SERVED AS CHIEF SCIENTIFIC
OFFICER AND HAS BEEN WITH THE
COMPANY SINCE 2007.
THROUGH HER ACADEMIC CAREERS HER
FOCUS HAS PRIMARILY FOCUSSED ON
ADDITION, NEURODEGENERATIVE
DISORDER SUCH AS ALZHEIMER'S AND
PARKINSON'S AND MOOD AND ANXIETY
DISORDERS AND METABOLIC
DISORDERS AND OBESITY.
SHE HOLDS A Ph.D. IN CLINICAL
NEUROPSYCHOLOGY FROM GEORGE
MASON UNIVERSITY IN FAIRFAX,
VIRGINIA.
THE THIRD IS PROFESSOR AT THE
UNIVERSITY SAN FRANCISCO.
AND HAS BEEN RECOGNIZED FOR HER
CONTRIBUTIONS TO HIV PUGH AND
THE ZIKA VIRUS INFECTIONS.
SINCE JANUARY 2020, SHE HAS
DEVOTED EFFORTS TO SARS COV2
RESEARCH.
HER WORK IS FOCUSSED ON
INFECTIOUS SARS COV2 AND
HARNESSING THE HOST RESPONSE FOR
NEW THERAPIES.
HER LAB ALSO DEVELOPED NEW RAPID
DIAGNOSTICS ON CRISPR AND PHONE
TECHNOLOGIES AND HAS BEEN ON THE
AMERICAN PHYSICIANS AND FELLOW
OF THE AMERICAN ACADEMY OF
MICROBIOLOGY.
AND THE FOURTH MEMBER I WANT TO
INTRODUCE TODAY IS A FULL
PROFESSOR IN THE DEPARTMENT OF
PSYCHIATRY WHERE HE HOLDS JOINT
APPOINTMENTS IN THE USF
DEPARTMENT OF CELLULAR AND
MOLECULAR PHARMACOLOGY AND THE
UCSF BIOLOGY INSTITUTE.
HIS RESEARCH IS FOCUSSED ON
UNDERSTANDING RECEPTOR MEDIATED
CELL BIOLOGICAL MECHANISMS AND
THE MECHANISTIC BASIS OF DRUG
ADDICTION.
HE HAS MADE SIGNIFICANT
CONTRIBUTIONS TO FIELD OF CELL
BIOLOGY, NEUROPSYCHIATRY,
ADDICTION MEDICINE AND
PHARMACOLOGY.
HE HAS RECEIVED MULTIPLE HONORS
INCLUDING ELECTION TO THE
NATIONAL ACADEMY OF MEDICINE IN
2011.
HE RECEIVED HIS M.D. AND Ph.D.
IN CELL BIOLOGY FROM YALE
UNIVERSITY IN THE NIH SCIENTIST
TRAINING PROGRAM.
THAT CONCLUDES MY INTRODUCTION
OF THE NEW MEMBERS AND THAT
MOVES ME TO MY PRESENTATION.
AT THIS POINT I'M GOING TO BE
SHARING MY SCREEN BUT I WILL
NEED FEEDBACK TO SEE IF YOU CAN
SEE MY SLIDES.
>>PERFECT.
>>TODAY I WANT TO GO OVER THE
SALIENT ISSUES THAT RELATE TO
THE INSTITUTE AND SOME OF THE
INT
INTERINSTITUTE NADA GETS
INVOLVED WITH AND THIS IS A
DISCUSSION COME AROUND AND
PRESENTING THE 2023 BUDGET
APPROPRIATED TO NIDA.
OUR BUDGET IN TERMS OF SEPARATE
AND THE REASON IS WHATEVER
PROJECTS SUPPORTED BY HEAL
RELATED TO OPIOID USE DISORDERS
HAVE TO BE APPROVED BY THE
OFFICE OF THE DIRECTOR WHICH IS
ACTUALLY THE ONE MAKING THE
FINAL DECISIONS OF WHAT GETS
FUNDED AND WHAT BUDGETS ARE
ALLOCATED FOR THE PROJECTS.
OVER ALL WE RECEIVED AN INCREASE
TO THE BUDGET.
BOTH FOR OUR BASE AND FUNDS
THROUGH HEAL TO TARGET OPIOID
USE DISORDERS AND OVERDOSES.
THE WAY THE FUNDS ARE ALLOCATED
VARIOUS SIGNIFICANTLY FOR
NON-FIELD RESEARCH VERSUS FIELD
RESEARCH.
THIS REFLECTS IN PART FIELD
RESEARCH HAS AN URGENCY TO
ADVANCE SCIENCE RIGHT NOW AS
FAST AS POSSIBLE CAN HELP
DECREASE THE NUMBER OF OVERDOSE
DEATHS THAT ARE PLAGUING THE
COUNTRY.
IN THE NON-HEAL RESEARCH WE HAVE
AN OPPORTUNITY TO HAVE GREATER
INVESTMENT IN SCIENCE AND BASIC
SCIENCE RESEARCH BUT ALSO DO
SIGNIFICANT INVESTMENT IN
EPIDEMIOLOGY SERVICES AND
CLINICAL TRIALS NETWORK.
ON THE OTHER HAND, THE FIELD
PORTFOLIO IS ON ACCELERATING
CLINICAL TRIALS THAT CAN HELP
DEVELOP GUIDELINES AND JUSTIFY
THE UTILIZATION INCLUDING THE
TREATMENT OF SUBSTANCE USE
DISORDERS.
WE'RE ALSO ACCELERATING THE
THERAPEUTICS FOR THE TREATMENT
OF OPIOID USE DISORDERS AND
OVERDOSES AND MORE RECENTLY WE
HAVE BEEN GIVEN THE FLEXIBILITY
TO ALSO USE HEAL FUNDS TO
ACCELERATE TREATMENT FOR
STIMULANT USE DISORDERS.
NIDA WANTED TO BE AWARE OF A NEW
POSITION TO DR. CRAN AT NIDA
DIVISION OF EPIDEMIOLOGY AND
SERVICES RESEARCH WHO NOW IS
GOING TO BE IN THE ROLE OF
DIRECTORS OF THE OFFICE OF
DIVERSITY AND DISPARITIES THAT
IN THE PAST WAS LED BY ALBERT
AVILA AND ALSO THE DEPUTY
DIRECTOR FOR THE OFFICE OF
RESEARCH TRAINING, DIVERSITY AND
DISPARITY.
IN TERMS OF LEADERSHIP WE'RE
ACTIVE IN THE EXECUTIVE OFFICER.
IS WE ARE SEARCHING FOR A NEW
EXECUTIVE OFFICER.
SIMILARLY, THE CLINICAL DIRECTOR
THE SEARCH IS ONGOING AND
FINALLY WE ARE FINALIZING THE
REVIEW PROCESS FOR THE
CANDIDATES PUT FORWARD FOR THE
SEARCH COMMITTEE OF THE DIVISION
OF THERAPEUTICS AND MEDICATION
AND HOPEFULLY BY NEXT COUNCIL
I'LL BE ABLE TO ANNOUNCE THE NEW
POSITIONS.
BEFORE I GO INTO SPECIFICS OF
NIDA I WANT YOU TO BE AWARE OF
THE CHANGES TO THE PEER REVIEW
CRITERIA AND THE INTENT IS TO
FOCUS THE PEER REVIEW ON
ASSESSMENT OF THE SCIENTIFIC AND
TECHNICAL MERIT OF THE GRANT
APPLICATIONS AND THE BURDEN
REVIEW.
IT ALSO TRIES TO MITIGATE THE
BIAS IN THE PEER-REVIEW PROCESS.
INSTEAD OF FIVE FACTORS WITH
SIGNIFICANT INVESTIGATOR AND
APPROACH THERE'S THREE FACTOR
THAT WILL BE EVALUATED.
THE IMPORTANCE OF RESEARCH AND
INTEGRATING WHAT WAS IN THE PAST
INNOVATION.
RIGOR WHICH S AND THE EXPERTISE
AND RESOURCES THAT RELATE TO THE
INVESTIGATOR AND TO THE PLACE
WHERE THEY'RE GOING TO BE DOING
THEIR RESEARCH.
AND WHEREAS THE OTHER -- THE ONE
IMPACTS WILL BE SCORED 1 TO 9
THE ONE WILL BE SCORED AS
APPROPRIATE FOR ADDITIONAL
RESOURCES NEEDED.
WE ARE AT THIS POINT, THE NIH IS
RECOMMENDING AND I WOULD URGE
YOU TO LOOK INTO IT AND IF YOU
HAVE ANY CONCERNS OR
SUGGESTIONS, THIS IS THE TIME TO
HEAR TO MAKE YOUR VOICE COUNT.
THE OTHER UPDATE IS ON THE
TRAINING INITIATIVE IT HAS
INVESTED OVER $3 BILLION IN 1166
PROJECTS.
YOU CAN SEE ALSO HOW THEY'VE
BEEN RAMPING UP.
AS A RESULT OF THAT, THIS
FUNDING HAVE BEEN ABLE TO FUND
1166 P.I.s, 234 INSTITUTIONS AND
SUPPORTED 952 BRAIN AWARDS.
IT HAS BEEN INCREDIBLY
PRODUCTIVE AND JUST LOOKING AT
THE NUMBER OF PUBLICATIONS YOU
CAN SEE HOW THEY'RE GOING UP.
AND THOUGH '22 LOOKS LOWER IT
HASN'T BEEN UPDATED.
IT'S CLEAR THE TECHNOLOGIES
DERIVED FROM THE BRAIN AS WELL
AS THE KNOWLEDGE IN THE
CIRCUITRY AND CELL
CLASSIFICATION IS BASICALLY
EFFECTING THE REST OF THE
NEUROSCIENCE FIELD INCLUDING THE
SUBSTANCE ABUSE FIELD ITSELF.
THE BRAIN MEETING IS JUNE 12 AND
13 AND URGE YOU TO LOOK AT THE
WEBSITE TO GET YOURSELF INFORMED
ON FUNDING OPPORTUNITIES AND GET
TO KNOW SOME OF THE RESEARCHERS
AND THE PEOPLE THAT ARE MANAGING
THE PROGRAM.
LET ME JUMP INTO NIDA RELATED
ISSUES.
I ALWAYS GIVE YOU AN UPDATE IN
THE FIRST COUNCIL OF THE YEAR
WHAT THE FUTURE HAS SHOWN US AND
OVER ALL THE NEWS IS GOOD
BECAUSE YOU HAVE BEEN HEARING
DURING THE COVID PANDEMIC
THERE'S BEEN A SIGNIFICANT
REDUCTION WE ADJUDICATE WE
BELIEVE ARE DUE TO THE
DISTANCING IMPOSED BY THE SOCIAL
ISOLATION AND CLOSING OF SCHOOLS
THAT PROTECT TEENAGERS FROM
TAKING DRUGS AND HAVING PEER
PRESSURE TO DO SO.
WE WERE VERY CONCERNED AS
TEENAGERS WENT BACK TO SCHOOL
WHICH HAPPENED VERY MUCH ALREADY
IN 2022 WHEN THE DATA FROM THIS
MONITORING THE FUTURE THE
EXPECTATION IS THE VALUES WOULD
GO BACK AND THEY HAVE NOT AND
THEY'VE BEEN STABLE FROM WHAT WE
SAW IN 2021, THE LOWEST SINCE
THE MONITORING THE FUTURE.
VERY FEW INDICATORS WHEN ONE
WENT BACK TO LEVELS SIMILAR TO
THE PANDEMIC ERA.
I WOULD SAY THE MOST NOTABLE ONE
WAS ALCOHOL USE IN 12 GRADERS.
INTERESTINGLY, NOR FOR 10th OR
9th GRADERS.
THIS WAS SPECIFIC FOR THE 12th
GRADERS.
WE DON'T KNOW HOW THESE LEVELS
WILL BE NOR WHAT WILL BE FROM
THE PERSPECTIVE OF DOWN STREAM
CONSEQUENCES FROM THE STRESS AND
MENTAL HEALTH CHALLENGES
REPORTED IN THE ADOLESCENT
POPULATION AND OTHER POPULATIONS
BUT CERTAINLY PERHAPS HIGHER
RATES AMONG THE AGE GROUPS
POST-COVID PANDEMIC.
I ALSO WANT TO TOUCH ON THE
ELECTIONS AND MANY VOTED ON
CANNABIS AND IT LOST AND WE HAVE
21 STATES WHO HAVE VOTED
RECREATIONAL MARIJUANA MAKING IT
LEGAL.
WE NOW HAVE 38 STATES WHO HAVE
APPROVED MEDICAL MARIJUANA.
YOU CAN SEE BASICALLY ALL THE
UNITED STATES HAS BEEN COVERED
WITH BLUES OR GREENS WHICH
ACTUALLY GIVES A PERSPECTIVE OF
WHAT SOME OF THE CHALLENGES ARE
AND OPPORTUNITIES FOR RESEARCH.
WE HAVE BEEN PREDICTING THAT
THESE LEGALIZATION IS GOING TO
RESULT IN AN INCREASE IN
MARIJUANA CONSUMPTION.
NOT SURPRISING, IT HAS
MATERIALIZED.
WE HAVE SEEN SIGNIFICANT
INCREASES IN MARIJUANA
CONSUMPTION AMONG AMERICANS.
WE HAVE NOT SEEN IT PER SE IN
ADOLESCENTS BUT WITH THE 18
YEARS OR OLDER OF ALL AGES AND
DEMOGRAPHICS.
WHAT'S INTERESTING WHAT IS
PORTRAYED BY THE DATA ANALYZED
IS THAT IF WE ARE TO BE LOOKING
AT IT WHAT ARE THE CONSEQUENCES,
IT IS NOT SO MUCH THAT
INCREASING NUMBER OF USERS.
THE NUMBER OF USERS OF THAT
REPORT BY USE OF MARIJUANA WHICH
TRIPLED BETWEEN 1992 AND 2020.
HE KNOWS AND I AGREE WHAT IS
WORRISOME IS DRAMATIC INCREASES
IN REGULAR USE OF MARIJUANA
WHICH ARE THE ONES ASSOCIATED
WITH MORE AFFECTS.
WHERE MONTHLY USERS QUADRUPLE
AND DAILY USERS INCREASED 14
FOLD.
THE BLUE LINES REPRESENT THE
AMOUNT CONSUMED BY AN
INDIVIDUAL.
THE PATTERNS AND HARMFUL
INCREASE WITH THE LEGALIZATION
OF MARIJUANA AND THE DOSES
PEOPLE ARE CONSUMING OF
MARIJUANA HAVE ALSO DRAMATICALLY
INCREASED.
THIS IS WORK THAT BECOMES
IMPORTANT.
WE NEED TO UNDERSTAND WHAT ARE
THE NEGATIVE CONSEQUENCES FROM
IT.
WE'VE ALSO PAID ATTENTION
PRIORITIZING THE POTENTIAL
NEGATIVE EFFECTS OF MARIJUANA
CONSUMPTION AMONG YOUNG PEOPLE,
CHILDREN, TEENAGERS AND PREGNANT
WOMEN.
INDEED, ONE OF THE REASONS WHY
IT LED US TO INITIATIVE THE ABC
STUDY IS TO HAVE A DRIED TO
ENABLE US TO MONITOR WHETHER
EXPOSURES TO DRUGS EARLY ON
DURING ADOLESCENCE AFFECTED
BRAIN DEVELOPMENT AND
CONTROLLING FOR FACTORS THAT
EXISTED PRIOR TO CONSUMPTION.
THAT'S A CRITICISM AND THEY SAY
THAT ADOLESCENTS USING MARIJUANA
ARE DOING WORSE ACADEMIC WISE
AND THE STUDY EVALUATING
TEENAGERS AND CHILDREN 9 TO 10
AND WE'LL ABLE TO DETERMINE IF
MAY HAVE A CORRELATION WITH POOR
PERFORMANCE AND WHETHER IT'S IN
ANY WAY CONTRIBUTING TO THE
MERGENCE OF PSYCHIATRIC
ILLNESSES AND HOW THOSE
TRAJECTORIES DIFFER AND AFFECT
THE DEVELOPMENT OF THE BRAIN.
IN PARALLEL, LAST YEAR WE
LAUNCHED THE HEALTHY BRAIN AND
DEVELOPMENT STUDY TO STUDY
WHETHER MARIJUANA IN A
LONGITUDINAL FASHION AND DURING
PREGNANCY AFFECTS NEONATAL
DEVELOPMENT.
THESE STUDIES SIDE BY SIDE ARE
VERY POWERFUL TOOLS WE CURRENTLY
HAVE AND FOR WHICH WE'RE
PARTNERING WITH COLLABORATIONS
WITH MULTIPLE INSTITUTES
INCLUDING THE NATIONAL INSTITUTE
OF ALCOHOL ABUSE AND ALCOHOLISM
AND INSTITUTES OF MENTAL HEALTH
AND SUPPORT FROM OTHERS.
THIS IS FOR SOLID DATA AND THERE
ARE OTHER AREAS FOR NIDA TO
PROMOTE RESEARCH ON DUE TO THE
FREQUENT RATES OF CONSUMPTION.
SO THESE ARE ILLUSTRATING THE
MAIN PRIORITY AREAS APART FROM
NEURODEVELOPMENTS WHERE WE ARE
SEEKING RESEARCH.
A PHARMACOLOGIC STUDY ON THE
COMPOUNDS UNDERSTANDING THEIR
AFFECT IN CELLULAR BIOLOGY AND
EPIDEMIOLOGICS AND METABOLISM
AND CONSEQUENCES AND
UNDERSTANDING WHAT ARE THE
FACTORS ASSOCIATED WITH
VULNERABILITY FOR CANNABIS USE
AND CANNABIS USE DISORDERS AND
NEGATIVE CONSEQUENCES GENETIC
AND SOCIAL DETERMINATES OF
HEALTH.
WE'RE INTERESTED IN BRAIN
DEVELOPMENT BUT THERE'S ALSO
EVIDENCE AND THERE'S BEEN A LOT
OF WORK GOING ON TO TRY TO
DETERMINE IF ADULTS THAT CONSUME
MARIJUANA HAVE NEGATIVE AFFECTS
ON THE BRAIN STRUCTURE OR
NEUROCHEMISTRY AND THIS IS A
STUDY THAT USES A RELATIVELY
NOVEL TRACER WITH TOMOGRAPHY TO
QUANTIFY THE SYNAPTIC DENSITY IN
THE BRAIN AND WAS NOVEL.
YOU CAN SEE HOW SIGNIFICANTLY
REDUCED THE SYNAPTIC DENSITY
THAT CONSUME CANNABIS IN OWLS
AND OTHER OTHER TECHNOLOGIES
INDICATE CONSUMPTION OF
MARIJUANA MAY BE HARMFUL TO
CERTAIN BRAIN REGIONS AND WE
TEND TO POLARIZE STATEMENTS LIKE
THIS BUT IT'S LIKELY THE AFFECTS
ARE ASSOCIATED WITH REGULAR
CONSUMPTION AND HIGHER DOSES.
WE HAVE LITTLE INFORMATION AS OF
NOW ON WHETHER THERE'S NEGATIVE
CONSEQUENCES ON THIS AREA.
AND WE NEED TO CONSIDER THE
AFFECTS OF CANNABIS ON THE BRAIN
ARE LIKELY TO BE AFFECTED BY THE
LIFE STAGE OF THE INDIVIDUAL AND
WE KNOW ALREADY FROM STUDIES WE
KNOW THERE'S SIGNIFICANT
DIFFERENCES ON THE WAY THAT
CANNABIS AFFECTS MEN AND WOMEN
AND WE NEED TO TAILOR
INTERVENTIONS ACCORDINGLY.
WE ARE ALSO PRIORITIZING TAKING
ADVANTAGE OF THE DIFFERENCES BY
WHICH THE STATES ARE LEGALIZING
MARIJUANA TO DETERMINE TO LOOK
AT WHAT IS ASSOCIATED WITH SAFER
PATTERNS AND RESEARCH ON POLICY
TO FLAG WHAT IS THE MOST
EFFECTIVE INTERVENTIONS TO
MINIMIZE HARMFUL AFFECTS AND
RECOGNIZING PEOPLE ARE USING
CANNABIS WHETHER IT IS APPROVED
OR NOT BY THE FDA THEY'RE USING
IT AND WE KNOW THAT CONSISTENTLY
AND PARTICULARLY THE MOST
FREQUENT INDICATION APPEARS TO
BE FOR PAIN.
IT BEHOOVES US AS A SCIENTIFIC
ORGANIZATION TO DO STUDIES THAT
CAN HELP DOCUMENT WHAT POTENTIAL
MAKE CANNABIS WORK THE ACTIVE
INGREDIENT, CBD OR THC AND THE
POTENTIAL FOR CANNABIS USE
DISORDERS OR FOR THE TREATMENT
OF PAIN OR INFLAMMATORY PROCESS
ASSOCIATED AMONG OTHERS WIN HIV.
LET THE JUMP BACK TO THE TWO
MOST AMBITIOUS STUDIES AT NIDA
IN PARTNERSHIP WITH OTHER
INSTITUTES.
ONE IS THE ADOLESCENT BRAIN
COGNITIVE DEVELOPMENT STUDY.
I GIVE YOU AN UPDATE ON EVERY
COUNCIL TO GET A SENSE OF WHERE
WE ARE.
THIS GIVES A SUMMARY OF THE
RETENTION AND COMPLETION OF
DIFFERENT CASES OF THE ABC.
IT'S QUITE REMARKABLE AND I DO
NOT KNOW OF ANY OTHER STUDY THAT
HAS BEEN ABLE TO KEEP THAT LEVEL
OF RETENTION.
97.6% HAVE BEEN RETAINED AND HAS
BEEN DEPOSITED ON AN ANNUAL
BASIS EXCEPT LAST YEAR AND WE
MISSED OUR DEADLINE.
THE DEPOSITION OF THE BRAIN
IMAGING DATA AND THE BEHAVIORAL
DATA FROM THE ABC WILL NOT
HAPPEN UNTIL 2023.
WE'RE AND THEY'RE WORKING
DILIGENTLY TO MAKE THIS HAPPEN
AS SOON AS POSSIBLE.
MEANWHILE YOU CAN SEE THE GROWTH
IN THE PUBLICATIONS AND YOU CAN
SEE THE INCREASE COMING FROM
NON-ABC INVESTIGATORS AND WANT
TO MAKE SURE PEOPLE THAT MAY NOT
BE AS FAMILIAR CAN NONETHELESS
TAKE ADVANTAGE OF THE DATA SETS.
INCREDIBLY IMPORTANT FINDINGS
HAVE HAPPENED.
I THINK PERHAPS TO ME THE MOST
RELATE TO HOW SOCIAL
DETERMINATES OF HEALTH ARE
INFLUENCING THE BRAIN
DEVELOPMENT AND COGNITIVE
PROCESSING OF THESE CHILDREN AND
HOW IT IDENTIFIES FACTORS THAT
SHOULD BE ACTIONABLE TO PREVENT
AFFECTS FROM LOW-INCOME FAMILIES
AND LACK OF OPPORTUNITYIES BUT
HAS COME OUT WITH RESEARCH AND
KNOWLEDGE RELEVANT TO THE
CHALLENGES WE'RE FACING AS IT
RELATES TO EVERYDAY LIFE FOR
TEENAGERS SUCH AS THE USE OF
SOCIAL MEDIA.
THERE'S BEEN AN ENORMOUS AMOUNT
OF CONCERN FOR THE INCREASING
UTILIZATION OF SOCIAL MEDIA BY
TEENAGERS AND LACKING AT USE AT
SOCIAL MEDIA OR SCREEN TIME HAS
BEEN ASSOCIATED PARTICULARLY
AMONG BOYS FROM THE ABC HAVE A
HIGHER RISK OF ANXIETY AND
DEPRESSION.
THERE'S FINDINGS THAT INDICATE
MANY HOURS OF VIDEO GAMING ARE
ASSOCIATED WITH BETTER
PERFORMANCE ON REACTION TIMES
AND WORKING MEMORY.
THE POTENTIAL BOTH FOR GOOD AND
BAD FOR THESE SOCIAL MEDIA
PLATFORMS TO INFLUENCE THE WELL
BEING OF ADOLESCENCE AND IT'S
RESEARCH LIKE THIS ONE
ULTIMATELY THAT CAN GIVE US A
PERSPECTIVE OF HOW TO TARGET IT.
AS WE KNOW IT'S LIKELY THERE'LL
BE SIGNIFICANT DIFFERENCES
BETWEEN ADOLESCENTS.
SOME WILL BE MORE VULNERABLE
THAN OTHERS AND MANY ARE NOT
JUST GOING TO BE RELATED TO
GENETICS AND BIOLOGY.
ALSO BY THEIR SOCIAL SITUATION
AND OTHER ALTERNATIVES AS A
TEENAGER.
FOR THE ABC WE LAUNCHED A
TWO-YEAR PILOT AND THAT WAS
COMPLETED AND WE PROVIDED THE
FUNDING AND I THINK IN SEPTEMBER
TO THE SITES THAT ARE GOING TO
BE FUNDED.
IT'S 27.
I HAVE A MISTAKE BECAUSE WE DID
INCREASE IT.
27 SITES THAT ARE GOING TO BE
FUNDED AND THEY ARE FINALIZING
THE PILOTING WORK AND HAVE TO BE
PASSED BY A CENTRALIZED IRB.
THE PROTOCOL HAS FINALIZED FOR
ONE TO THREE VISITS.
THE ENROLLMENT OF THE STUDY
COHORT ARE EXPECTED IN MAY.
THESE THE NUMBERS IN TERMS OF
ENROLLMENT FOR THE PILOTING OF
THE DIFFERENT SITES THAT HAVE
BEEN GRANTED THE FUNDS.
THIS IS HIGHLIGHTING A PROJECT
DONE WITH OTHER INSTITUTES AND
WITH PARTNERSHIP FUNDING FROM
THE HEAL INITIATIVE.
THAT LEADS ME TO JUMP INTO THE
OVERDOSE CRISIS.
THIS IS THE MOST RECENT DATA
FROM CDC THAT GOES TO THE LAST
12 MONTHS FROM OCTOBER 2022.
THE INCREASE IS NOT THE SAME AS
THE FIRST YEAR AND SECOND YEAR.
THE RATE OF INCREASE SEEMS TO
HAVE BEEN SLOWING DOWN EACH
TELLS YOU THE OVERDOSE
MORTALITY.
MANY OF THESE OVERDOSE DEATHS
ARE OBSERVED IN COMBINATION WITH
FENTANYL.
IT DOES HIGHLIGHT IT'S SYNTHETIC
DRUGS AND FENTANYL THE MAIN
CAUSE OF MORTALITY.
73,000 PEOPLE DIED IN THE UNITED
STATES IN ONE YEAR FROM
FENTANYL.
OF THE DEATHS FROM COCAINE AND
AMPHETAMINE IT'S ESTIMATED THE
MAJORITY HAD FENTANYL ON BOARD
AND YOU SEE A RISE IN MORTALITY
FROM COCAINE AND
METHAMPHETAMINE.
THIS YEAR WE'RE SEEING GREATER
RISES IN COCAINE LIKELY TO BE IN
PART DUE TO THE AVAILABILITY OF
THE DRUGS ACROSS THE COUNTRY.
HEROIN CONTINUES TO GO DOWN.
THERE'S A DECREASES IN DEATH AND
THE OVERDOSE MORTALITY FROM
METHADONE CONTINUES TO GO DOWN.
THIS IS NOT BECAUSE WITH THE
COVID PANDEMIC WITH THE V.A. AND
SAMHSA MADE IT EASIER TO HAVE
TAKE-HOME METHADONE.
IT WAS CONCERNED THAT WOULD LEAD
TO INCREASE IN MORTALITY.
THE DIDN'T MATERIALIZE AND SO
WHAT ARE THE STRATEGIES FROM THE
PERSPECTIVE OF SCIENCE AND HOW
DO WE PROMOTE RESEARCH TO HELP
ADDRESS IT?
BOTTOM LINE IS WE HAVE TOOLS TO
PREVENT OVERDOSES AND RECAN
REDUCE THE RISK OF OVERDOSE BUT
YOU HAVE TO HAVE PATIENTS KEEP
ON TAKING IT.
ALSO, NALOXONE ADMINISTRATION IF
YOU GIVE IT IN THE RIGHT DOSE IN
A TIMELY FASHION, YOU WILL SAVE
THE LIFE OF THAT PERSON.
THOSE ARE THE NUMBERS WE GET AND
I PRESENTED IT LAST COUNCIL AND
WE CAN'T IGNORE THE NUMBER OF
PEOPLE THAT HAVE DIED FROM AN
OVERDOSE THAT RECEIVED
MEDICATIONS FOR OPIOID USE
DISORDER IN AVERAGE LESS, 16.4%
AND SOME HAVING LOWER LEVELS OF
PRESCRIPTION AND THESE ARE
AFRICAN AMERICAN.
SIMILARLY, LOOK AT THE NUMBERS
OF INDIVIDUALS WHO DIED FROM AN
OVERDOSE WHO RECEIVED NALOXONE.
IT'S LESS THAN 20%.
WHAT DO WE NEED TO DO TO EXPAND
ACCESS TO MEDICATION AND IMPROVE
RETENTION AND EXPAND AND BE MORE
SUCCESSFUL IN ADMINISTERING
NALOXONE.
WE HAVE INITIATED PROJECTS AND
EXPAND CLINICAL TRIALS TO DO
UNDER THE NIDA CLINICAL TRIAL
NETWORK AND EXPAND THE NUMBER OF
SITES.
THESE ARE BEING PERFORMED BY THE
CLINICAL TRIAL NETWORK AND THE
ONE I'LL BE HIGHLIGHTING IS TO
UNDERSTAND THE HOW TO TREAT
THRESHOLD OPIOID USE DISORDER OR
MILD OPIOID USE DISORDER.
THIS IS AN AREA WHERE WE HAVE
LIMITED RESEARCH AND THERE'S
DRUGS WITH FENTANYL OCCASIONAL
USE OF OPIOID I AM POSES A RISK
FOR OVERDOSES.
FOR THE NETWORK AND THERE'S
SEVERAL PROJECTS THAT GO FROM
RANDOMIZED CLINICAL TRIALS TO
HOW TO IMPLEMENT MEDICATIONS FOR
OPIOID USE DISORDER TO WHAT ARE
THE MODELS WE SAW TO BETTER OUR
RETENTION OF PEOPLE IN TREATMENT
AND MINIMIZE REINCARCERATION.
THIS HAS BEEN AN EXTRAORDINARY
SUCCESSFUL INITIATIVE NOT JUST
IN TERMS OF RESEARCH FINDINGS
BUT MORE IMPORTANTLY THROUGH THE
PARTNERSHIP WE HAVE BEEN ABLE TO
SLOWLY AND FINALLY START TO
CHANGE THE CULTURE IN THE
SETTINGS TO BE MORE OPEN TO
PROVIDING TREATMENT FOR
SUBSTANCE USE DISORDERS AND TO
PROVIDE WITH MEDICATIONS FOR THE
TREATMENT OF OPIOID USE DISORDER
AS WELL AS RECOGNITION OF THE
IMPORTANCE OF LINKAGE OF CARE TO
THE COMMUNITY ONCE THEY LEAVE
THE JAIL SYSTEM.
THE FINAL ONE IS THE COMMUNITY
STUDY WHICH HAS FOUR STATES TO
DEVELOP MODELS THAT CAN MAKE
JUSTICE, HEALTH CARE, STATE AND
COMMUNITY PROVIDERS IN A
HARMONIZED WAY AS A MEANS TO
REDUCE OVERDOSE DEATHS AND
DESPITE THE CHALLENGES OF THE
COVID PANDEMIC HAS BEEN ABLE TO
MAKE MAJOR CONVENIENCES.
-- ADVANCES.
WE WANT TO COME BACK TO THE DATA
AGAIN.
WE GUIDE FROM THE BASIC
KNOWLEDGE AND OUR UNDERSTANDING
TO ARRIVE AT INTERVENTIONS THAT
WILL BE NEEDED AND I WANT TO
EMPHASIZE FENTANYL AGAIN.
THIS FENTANYL AND IT'S DRIVING
THAT INCREASING DRIVE IN
OVERDOSE MORTALITY.
THIS IS EMERGING IN 2016 AND
IT'S GONE UP AND UP AND UP AND
PEOPLE ARE DYING.
SO THIS IS DRIVEN BY TWO
FACTORS.
ONE IS PHARMACOLOGIC AND FOR US
AS AN AGENCY UNDERSTANDING THE
PHARMACOLOGIC CHARACTERISTICS AS
A WAY OF TAILORING
INTERVENTIONS.
THE OTHER ONE IS THE MASSIVE
PROFIT DEALING WITH HAS GIVEN TO
THE MARKET THAT'S A DIFFERENT
TYPE OF CHALLENGE.
FROM THE PERSPECTIVE OF
PHARMACOLOGY, WE KNOW FENTANYL
IS VERY POTENT.
THE NUMBER THAT IS USED IN
GENERAL IS 50 TIMES MORE POTENT
THAN HEROIN.
WHAT THAT MEANS IS A 2 MILLIGRAM
DOSE OF FENTANYL CAN BE LETHAL.
SO WE HAVE A VERY POTENT DRUG
THAT CAN RESULT IN DEPRESSION
AND OVERDOSE AND DEATH AT
RELATIVELY LOW DOSE AND IT'S
ALSO A HIGHLY REWARDING DRUG
THAT CAN PRODUCE ADDICTION.
WE'RE SEEING PEOPLE THAT ARE
SEEKING OUT FENTANYL AND WHEN
THEY COMBINE IT WITH OTHER DRUGS
THERE'S NO STANDARD.
THE CONTENT OF FENTANYL OF THE
PRODUCTS VARIES ENORMOUSLY AND
THEY FOUND A RANGE OF DOSES FROM
.02 TO .05 MILLIGRAM TO KILL YOU
TWICE AND THIS IS THE ELEMENT
WHEN SOMEONE CONSUMES DRUGS.
ANOTHER ASPECT THAT HAS
ATTRACTED ATTENTION FROM THE
LOOKING AT THE OVERDOSE THIS
GETS INTO THE BRAIN AND CAUSES
RESPIRATORY DEPRESSION AND THE
TIME TO ADMINISTER NALOXONE
CONSTRAINED AND THIS IS WHERE
RESEARCHERS WERE THINKING HOW WE
CAN TACK A LOT.
THE OTHER ASPECT IS OVERDOSE
REVERSES FROM FENTANYL HIGHER
DOSES.
THIS IS CONSISTENT WITH ANIMAL
DATA.
WE NEED TO GIVE HIGHER DOSE OF
NALOXONE TO REVERSE RESPIRATORY
DEPRESSION AND THEY FREQUENTLY
REQUIRE MULTIPLE DOSES AND THIS
IS BEING REPORTED THROUGH THE
LITERATURE AND WHAT WE KNOW IS
NALOXONE USE HAS BEEN GOING UP
AND UP AND THERE'S INSTANCES
WHERE MORE THAN 10 DOSES HAD TO
BE REPEATED.
THE OTHER COMPONENT THAT IS
RELEVANT IS THE PHYSICAL
DEPENDENCE PRODUCED BY FENTANYL
BECAUSE OF THE HIGH POTENCY IS
STRONGER THAN HEROIN.
IT'S A CHALLENGE TO GET INTO
TREATMENT THOSE WITH THIS
DISORDER AND THERE'S SUCCESS
WITH BUPRENORPHINE AND THE RATE
OF RELAPSE WITH PEOPLE TAKING
BUPRENORPHINE THE
DISCONTINUATION IS HIGHER THAN
THOSE WITH FENTANYL USE DISORDER
AND THERE'S EVIDENCE SOME
INDIVIDUALS THE INITIATION OF
BREW PREN -- BUPRENORPHINE IS
BEING EFFECTIVE AND THE DIAGRAM
JUST PUBLISHED RECENTLY BRINGS
FORWARD THE NOTION OF HOW WE CAN
START TO LOOK AT IT AND LOOKED
AT FENTANYL GETTING TO THE BRAIN
RAPIDLY AND THE LIPO PHILIC
NATURE ALLOWS IT TO INSERT
ITSELF IN THE MEMBRANES AND
ACCUMULATE BY THE SITE OF THE
RECEPTOR.
IT'S SURROUNDED BY AN ACQUEOUS
ENVIRONMENT AND FENTANYL ALSO
GETS THERE AND BUPRENORPHINE.
WHEN YOU GIVE NALOXONE IT GOES
TO THE SITE AND THROWS OUT
WHETHER IT IS BOUND TO MORE TEEN
OR FENTANYL.
AND NALOXONE CANNOT GET ITSELF
TO THE MEMBRANE AND THE FENTANYL
MOVES TOWARDS OCCUPYING THE SITE
AND THEY EXPLAIN THIS MAY BE THE
REASON WHY WHEN YOU GIVE
NALOXONE WITH FENTANYL YOU
ACTUALLY CAN RESTORE
RESPIRATION.
BUT IN THE CASE OF FENTANYL,
ONCE YOU MOVE NALOXONE OUT OF
THE PREPARATION, YOU AGAIN SEE
THE RESPIRATION GOES DOWN.
TO THE EXTENT THIS IS AN ISSUE
THAT COULD EXPLAIN WHY AND
THERE'S MAYBE A NOTION THAT
PERHAPS LOOKING AT OPIOIDS THAT
HAVE THE LIPOFELICITY MAY HAVE
AN INTERVENTION TO GET RID OF
THE ACCUMULATION BY THE RECEPTOR
SUCH THAT IF YOU WERE DO GIVE
THIS ONE WOULD BE BUPRENORPHINE
SUCH THAT YOU WILL NOT PRODUCE
THIS BUMPING UP WITH FENTANYL
AFTER THE DRUG HAS BEEN REMOVED.
AND IT HIGHLIGHTS WHY IT'S
IMPORTANT FOR US TO ADVANCE
BASIC PHARMACOLOGY AND IT'S
IMPORTANT TO ADVANCE ALTERNATIVE
MEDICATIONS FOR REVERSAL AND
IT'S NOT JUST FENTANYL BUT THE
ENORMOUS PROFITS COMING ABOUT BY
THE SALE OF FENTANYL.
THIS IS BECAUSE YOU DON'T HAVE
TO CULTIVATE ANYTHING AND SUPPLY
CHAINS ARE ABSENT.
THE SYNTHESIS OF FENTANYL IS
RELATIVELY EASY.
AS A RESULT YOU HAVE WHAT ISSESE
TO GET IN OTHER COUNTRIES AND
CAN BE TRANSPORTED EASILY AND TO
THE HIGH POTENCY OF FENTANYL HAS
BECOME AN INCENTIVE FOR DRUG
DEALERS TO STOP OTHER DRUGS THAT
ARE HARDER TO PRODUCE, LIKE
COCAINE OR HEROIN THEY'RE
DILUTING THOSE DRUGS AND A BIT
OF FENTANYL WILL MAKE A POWERFUL
DRUG AND THE PROFIT SO MUCH
LARGER WITH FENTANYL THAN WITH
ANY OTHER DRUG WE KNOW OF
INCLUDING ILLICITLY MANUFACTURED
DRUGS AND THEY'RE DISGUISING THE
MANUFACTURING OF FILLS WHICH ARE
BASICALLY FENTANYL.
THESE PEOPLE ARE NOW VULNERABLE
TO HAVING AN OVERDOSE.
OVERDOSE FATALITIES HAVE
INCREASED BY TEENAGERS AND IT
KEEPS GOING UP.
THIS IS DRIVEN LIKELY BY
TEENAGERS BECAUSE THEY CONSUME
STIMULANTS AND THEY MAY BE
OCCASIONAL LIKE PEOPLE NOT DRUG
USERS MAY OCCASIONALLY CONSUME
THESE DRUGS THEY BUY FROM THE
WEB BECAUSE THEY CANNOT GET
PHYSICIANS TO PRESCRIBE THEM.
THIS MAKES THE WHOLE CHALLENGE
OF CONTROLLING THE OVERDOSE
CRISIS WORSE.
I WANT TO FOLLOW UP ON THE DEATH
OF TEENAGERS AND YEARS LOST AND
IT'S BASICALLY DOUBLED.
PERHAPS MORE THAN DOUBLES.
I'M SHOWING IT HERE THAT AND
IT'S NOT JUST A NUMBER OF KIDS
DYING BUT THERE'S A HUGE IMPACT
IN LIVES LOST.
I THINK IT DESERVES ATTENTION IN
GENERAL AND I WANT TO PUT IT IN
YOUR BRAINS, MALES HAVE A
GREATER RATES OF OVERDOSE
MORTALITIIES THAN FEMALES AND
IT'S ACTUALLY THE RATE OF
MORTALITY FROM OVERDOSES THE
DIFFERENCE BETWEEN MALES AND
FEMALES IS LARGER IN OVERDOSE
MORTALITY.
THE DIFFERENCE IS DIFFERENT IN
THE PATTERNS OF CONSUMPTION OR
OPIOID USE DISORDER.
UNDERSTANDING THE PATTERNS AND
HOW THEY'RE TAKING THE DRUGS IN
GREATER RISK ANOTHER ITEM
RELEVANT WE'RE SEEING MORE AND
MORE DRUG COMBINATIONS CAUSING
PEOPLE TO DIE AND DRUGS
CONTRIBUTING MORE TO OVERDOSES.
THE ONE THAT'S GENERATED A LOT
OF ATTENTION IS XYLAZINE IS A
DRUG ASSOCIATED WITH SEVERE VASO
CONSTRICTION RESULTING IN LIMB
AMPUTATIONS.
THE NUMBER OF DEATHS HAVE BEEN
GOING UP.
AND THE DEATHS THAT HAVE
XYLAZINE HAVE GONE UP AND 90% OF
THE DEATHS WITH XYLAZINE ARE
ASSOCIATED WITH OTHER DRUGS AND
THIS IS 2020 AND THE NUMBER OF
DEATHS IN THE NUMBER OF STATES
WHERE THERE WAS AT LEAST ONE
XYLAZINE DETECTED RESPONSIBLE
FOR OVERDOGS DEATHS.
AND THERE'S STUDIES TO
UNDERSTAND WHY DO THEY MIX WITH
FENTANYL AND WHAT HAS BEEN
REPORTED MORE OR LESS
CONSISTENCY IS TO PROLONG THE
AFFECTS FENTANYL AND THIS COULD
ENSURE THE DRUG IS NOT CLEARED
FROM THE TISSUE.
THIS IS A FIELD THAT REQUIRES
MORE ATTENTION.
AND THIS IS WHEN THE PRESIDENT
SIGNED INTO LAW HR2617 THE
CONSOLIDATED APPROPRIATIONS ACT
FOR 2023 IN WHICH ELIMINATED THE
WAIVER AND REMOVED THE
BUPRENORPHINE PRESCRIBING AND
WHAT WE NEED SO UNDERSTAND IS
THE STATES CAN IMPLEMENT AS THEY
WANT.
IT IS POSSIBLE THAT WHERE SOME
STATES MAY NOT REQUIRE THE X
WAIVER AND REMOVE THE PATIENT
CAP, OTHER STATES MAY NOT BE
DOING THAT AND THIS OFFERS FROM
THE RESEARCH PERSPECTIVE AN
OPPORTUNITY TO UNDERSTAND HOW
THE IMPLEMENTATION OR LACK OF
WILL INFLUENCE THE OUTCOMES OF
THE VARIOUS STATES.
WITH THAT I HAVE MY LAST SLIDE.
MORALS THE SAME SLIDE BUT NOT
IDENTICAL AND I WANT EVERYBODY
TO HAVE IT IN FRONT OF THEIR
BRAIN IT ADDRESSES WHAT ASPECTS
OF SCIENCE WE NEED TO MOVE
FORWARD.
HOW THE CRISIS WE'RE LIVING WITH
THE OVERDOSE IS FORCING US TO
THINK IN DIFFERENT WAYS.
WE NEED TO CONTINUE DEVELOPING
RESEARCH AND SCIENCE BECAUSE IF
WE DON'T, PATIENT WHO'S HAVE
SEVERE PAIN WILL REFER TO
ILLICIT OPIOIDS WHICH ARE
DANGEROUS.
WE NEED TO CONTINUE ON RESEARCH
AND NOT JUST FROM IMPLEMENTATION
AND SERVICES RESEARCH WHICH IS
CRUCIAL BUT ALSO FROM THE
PERSPECTIVE OF NEW TREATMENTS
FOR OPIOID USE DISORDER WHETHER
NEW FORMATIONS, NOVEL TARGETS
THAT CAN IMPROVE THE WELL BEING
OF AN INDIVIDUAL AND IMPROVE THE
LIKELIHOOD OF STOPPING TAKING
DRUGS EVEN IF IT'S NOT LEADING
TO ABSTINENCE AND WE ALSO HAVE
ADVANCES ON HOW TO DELIVER
TECHNOLOGIES LIKE CURRENT
STIMULATION OR ULTRA SOUND
STIMULATION AND EXPLORING THE
WAYS WE CAN USE THEM BY
THEMSELVES OR IN COMBINATION
WITH MEDICATIONS TO IMPROVE
RETENTION IS AN AREA LIKELY TO
LEAD TO GREATER SUCCESS.
IT'S OBVIOUS ALSO AS MORE PEOPLE
CONSUME COCAINE AND
METHAMPHETAMINE AND MANY IN
COMBINATION WITH FENTANYL BUT
MANY DIDN'T KNOW THEY WERE
CONSUMING FENTANYL.
THEREFORE THE URGENCY TO
INSTIGATE TREATMENT WE CURRENTLY
DO NOT HAVE MEDICATIONS FOR
OTHER SUBSTANCE USE DISORDER
APART FROM ALCOHOL AND OPIOIDS
AND OVERDOSE TREATMENTS IT'S
BECOME HARDER TO REVERSE
OVERDOSES WHERE IT'S COMBINED
WITH OTHER DRUGS.
WE'RE SEEING CAPITOL HILLING
EXIST WHEN PEOPLE ARE OVERDOSING
WITH -- WE'RE SEEING CHALLENGES
THAT EXIST WHEN PEOPLE ARE
OVERDOSING WITH FENTANYL AND
WHEN WE LOOK AT ISSUES RELATED
TO OVERDOSES IS PREVENTION AND
PREVENTION OF DRUG USE IS
CRUCIAL FOR ADDRESSING THE
OVERDOSE CRISIS.
I SHOWED THE DATA ON ADOLESCENTS
FOR THAT REASON.
IT'S CHILLING TO SEE THAT
MORTALITY FROM TEENAGERS FROM
FENTANYL OVERDOSES AND YET DRUG
USE CAN BE PREVENTED AND YET WE
ARE NOT IMPLEMENTED ALREADY
DEVELOPED EVIDENCE BASED
PREVENTION INTERVENTION.
THE QUESTION IS WHAT TYPE OF
SCIENCE CAN HELP US INCENTIVIZE
SOME OF THE PREVENTION MEASURES
AND WHAT OPPORTUNITIES DO WE
HAVE OF DEVELOP NOVEL PREVENTION
INTERVENTION TO TAKE ADVANTAGE
OF THE TECHNOLOGIES WE HAVE
AMONG OTHERS BY EXCESS OF
WEARABLES OR ACCESS OF
APPLICATIONS THAT COULD DECREASE
COST AND MAKE THE INTERVENTION
MORE ACCESSIBLE.
TWO TOPICS IN GENERAL ARE DATA
SCIENCE AND WE'RE FASCINATED
WHAT WE CAN DO APPLYING
ARTIFICIAL INTELLIGENCE WITH
GOOD QUALITY DATA.
HOW TRANSFORMATIVE IT IS.
WE NEED TO RELATE TO DATA TO
SUBSTANCE USE DISORDERS IN
GENERAL AND HAVE DATA ON WHAT'S
HAPPENING IN THE COUNTRY RELATED
TO OVERDOSE MORTALITY OR THE
TYPES OF DRUGS EMERGING.
AND IT WOULD BE GREAT IF WE HAD
INFORMATION THAT PERTAINED TO
KNOW WHEN TO INTERVENE AND
UNDERSTAND IF OUR INTERVENTIONS
ARE HAVING EFFECT.
I THINK AT THE END OF THE DAY
WHAT COVID AND THE CRISIS IS
MAKING US AWARE OF AS WE'RE
SEEING THE EMERGENCE OF PATTERNS
OF DRUG CONSUMPTION SO DANGEROUS
MANY ARE DRIVEN BY WHAT WE HAVE
RECOGNIZED AS SOCIAL
DETERMINATES OF HEALTH.
AND PEOPLE THAT ARE MORE
VULNERABLE HAPPEN TO BE MORE
NEGLECTED.
NEGLECTED BECAUSE OF LACK OF
ECONOMIC OPPORTUNITIES.
NEGLECTED BECAUSE OF
DISCRIMINATION AND STIGMA AND
UNDERSTANDING HOW THOSE
PRACTICES INCLUDING
CRIMINALIZATION OF INDIVIDUALS
THAT TAKE DRUGS NEGATIVELY
INFLUENCES THE OUTCOME OF THAT
PERSON AND IMPACT THE COMMUNITY
AND COULD ONE DAY AND HOPEFULLY
NOT FAR FROM NOW CHANGE THE WAY
WE ADDRESS DRUG USE IN OUR
COUNTRY.
THANK YOU FOR YOUR ATTENTION AND
I'M GOING TO STOP SHARING SO YOU
CAN ASK QUESTIONS.
>>I HAVE A QUESTION ABOUT
XYLAZINE.
IT SEEMS IT'S 40 TIMES MORE
POTENT THAN FENTANYL AND MAKING
AN APPEARANCE IN OHIO AND D.C.
AND I DON'T KNOW WHAT THE MAP
WILL LOOK LIKE A YEAR FROM NOW.
WHAT HAVE YOU HEARD ABOUT THAT?
>>THERE'S EMERGENCE IN CERTAIN
STATES AND AREAS AND LOCATIONS.
WE DON'T KNOW THE NATURE OF THE
ILLICIT MARKET AND ONE AREA
WE'VE HAD DISCUSSIONS WITH ONDCP
AND CDC IS HOW TO GENERATE WHAT
CAN GIVE US A PULSE OF THE TYPES
OF DRUGS EMERGING AND HOW
RAPIDLY THEY ARE CHANGING.
I DON'T THINK WE REALLY KNOW
BECAUSE WE'RE NOT SYSTEMATICALLY
MEASURING IT.
>>I THOUGHT I'D BRING IT UP IN
CASE PEOPLE HAVE INFORMATION TO
SHARE.
WE'RE SEEING A COUPLE THINGS
PUBLISHED BUT NOT TOO MANY.
>>AMAZING AND WONDERFUL TALK.
I WAS STRUCK BY THE CANNABIS
DAILY USER RISE, 14 TIMES
INCREASE IN CANNABIS AND OF
COURSE THE AVAILABILITY AND
GETTING NEW USERS BUT 14 TIMES
IS DRAMATIC.
I DON'T THINK THE OLD DATA OF
CANNABIS BEING A GATEWAY DRUG
HAS GONE AWAY IN TERMS OF HOW
ACCESS AND AVAILABILITY WILL
COMPOUND OUR PROBLEMS EVEN WITH
THE OTHER ON THE HEELS OF THE
OTHER DRUGS USED AND ESCALATION
OVER TIME.
MY QUESTION IS THE INCREASE IN
THE TRANSITION TO DAILY USE
THERE'S A NEED TO UNDERSTAND
THAT BETTER IN TERMS OF THE
NEUROBIOLOGY AND TO DO STUDIES
AND IMAGING AND UNDERSTANDING
EARLY TARGETS.
I'M WONDERING IF YOU ALL HAVE
BEEN THINKING ABOUT THAT, I KNOW
HAVE YOU AND WHETHER THERE'S
SOME THOUGHTS IN PRIORITIES IN
THAT REGARD.
>>ABSOLUTELY AND THANK YOU FOR
THE QUESTION.
THERE WAS A RECOMMENDATION AND
THAT ANY INVESTIGATOR DOING
RESEARCH MY ONE AND FUNDED BY
NIDA USE A STANDARD DOSE.
THE STANDARD DOSE WE'RE
PROPOSING IS 5 MILLIGRAMS OF
THC.
WITH THE UNDERSTANDING THERE'LL
BE A RELATIVELY LARGE MARGIN OF
ERROR IN THE CONSUMPTION PATTERN
BUT THAT'S THE FIRST STEP TO TRY
TO GET DATA THAT ACTUALLY GETS
US AN IDEA OF THE DOSES PEOPLE
ARE CONSUMING OF TCH.
IN THE PAST THE WAY WE'RE DOING
IT SAYING DO YOU CONSUME
MARIJUANA OR NOT BUT THERE'S NO
ESTIMATION OF THE PATTERNS OF
CONSUMPTION AND YET WE KNOW
DOSES MAKE A BIG DIFFERENCE.
AND DOES IT EMERGE AS IT RELATES
TO THE SYNDROME SPECIFICALLY
ASSOCIATED WITH HIGH CONSUMPTION
OF NON-THC OR THE PSYCHOSIS
ASSOCIATED WITH THC.
THAT'S THE FIRST MOVE WE DID TO
STANDARDIZE METRICS TO COMPARE
FINDINGS FROM ONE STUDY TO THE
OTHER AND REQUESTING THE
DEVELOPMENT OF A REGISTRY SO WE
CAN LEARN ON POPULATION SCIENCE.
WE HAVE LITTLE INFORMATION AS IT
RELATES TO THE USE OF MEDICAL
MARIJUANA.
WE KNOW PAIN IS THE MAIN REASON
BUT THOUSAND IT AFFECT THE
PATTERNS OF CONSUMPTION OF OTHER
DRUGS OR THEIR UTILIZATION OF
OTHER MEDICATIONS.
THAT'S AN AREA WHERE WE HAVE
LITTLE INFORMATION AND WE WANT
TO COMPARE THAT AND INCENTIVIZE
RESEARCHERS TO PAY ATTENTION TO
ABOUT TO THE CONSEQUENCES OF THE
HIGH CONSUMPTION OF THC.
>>I HAVE A QUICK QUESTION
REGARDING HIV INFECTION AND
WHETHER WE SEE A CHANGE IN NEW
INFECTIONS OR HIV MANAGEMENT AND
WHAT'S THE USE OF INTENTIONAL
AND UNINTENTIONAL OVERDOSES AND
IS THERE GOOD RESEARCH I CAN
GET?
>>AS IT RELATES TO THE PATTERNS
OF DRUG USE THE INCIDENTS OF HIV
FROM THE PERSPECTIVE OF THE RISE
WE'RE OBSERVING ON
METHAMPHETAMINE IN THE COUNTRY
IS ASSOCIATED WITH A SIGNIFICANT
INCREASE RISK OF HIV.
THAT STEEMZ TO BE THE SINGLE
FACTOR THAT HAD CHANGE THE MOST
IN TERMS OF INCREASING THE RISE
OF HIV AMONG DRUG USERS.
IN THE PAST WE PAID A LOT OF
ATTENTION TO INJECTION DRUG USE
BUT APPARENTLY WHAT
METHAMPHETAMINE IS DOING IS
PROMOTES SEXUALLY RISKY
BEHAVIORS AND PEOPLE WHO USE
METHAMPHETAMINE AND MEN THAT
HAVE SEX WITH MEN DESCRIBE THIS
WHEN THEY WANT TO ENGAGE IN
SEXUALLY RISKY BEHAVIOR THEY MAY
CONSUME METHAMPHETAMINE.
FROM THAT PERSPECTIVE AND FROM
THE PERSPECTIVE OF OPIOIDS
ITSELF, WE HAD SEEN AN INCREASE
IN INJECTION DRUGS FROM 2010,
2011 ASSOCIATED WITH AN INCREASE
IN HEPATITIS C BUT NOT SO MUCH
ON HIV.
OVER ALL, THE INCIDENTS OF HIV
AMONG INJECTION DRUG USE HAS
BEEN STABLE.
WE DO SEE DIFFERENCES ACROSS THE
COUNTRY AND IN MARYLAND THERE
WAS AN INCREASE IN THE CASES OF
HIV FROM DRUG USE AND SOME ARE
RELATED TO PRACTICES SUCH AS
SYRINGE EXCHANGE PROGRAMS AND
YOU SEE THAT AREA HAVING AN
INCREASE IN HIV.
TO YOUR OTHER QUESTION ABOUT
WHAT WE KNOW ABOUT THE
COMBINATION OF HIV AND DRUG USE
IN TERMS OF INTENTIONAL OR
NON-INTENTIONAL OVERDOSES.
WE KNOW IN GENERAL INTENTIONAL
OVERDOSES, SUICIDE ACCOUNT FOR
15% AND PROBABLY THAT'S A LOW
ESTIMATE AND PEOPLE WITH HIV AND
COMORBIDITIES FROM GROUPS THAT
ARE STIGMATIZED HAVE AN INCREASE
AND THOSE WITH PSYCHIATRIC
DISORDERS THAT ARE STIGMATIZED.
BUT SPECIFICALLY WHAT IS THE
RATE FOR RISK FOR INTENTIONAL
OVERDOSE ON HIV?
I THERE'S A NO NUMBERS I RECALL
SEEING BUT WE'LL LOOK AT IT
BECAUSE IT'S IMPOSSIBLE TO HAVE
A SYSTEMATIC LOOK AT EVERYTHING
BUT I DON'T RECALL ANYONE
MENTIONING ANY NUMBER.
>>TWO COMMENTS.
ON YOUR LAST SLIDE YOU MENTIONED
CRIMINALIZATION AND STIGMA.
AND BC AND CANADA JUST
DECRIMINALIZED POSSESSION OF
SMALL AMOUNTS OF WHAT WE CALL
ILLICIT DRUGS INCLUDING THE
DRUGS WE'RE TALKING ABOUT NOW SO
IT WILL BE FASCINATING WHAT
HAPPENS THERE IN TERMS OF ACCESS
TO TREATMENT AND HARM REDUCTION
AND ALL THAT.
TWO IS YOU ALSO SPOKE ABOUT THE
TIMELINESS OF DATA WHICH I AGREE
IS SO IMPORTANT.
I WOULD ADD THE CRITICAL NEED TO
PAY ATTENTION THE QUALITY OF
DATA IS SO UNEVEN IN THE GROUPS
WHETHER RURAL FOLKS AND THERE'S
INDIGENOUS DATA GENOCIDE I WANT
TO ENCOURAGE PEOPLE TO CHECK
OUT.
>>DID THE DATA RELIABLE OR IS
THERE ERROR AND EVERYTHING WILL
PERPETUATE THE ERROR AND THERE'S
AN ISSUE OF NOT BEING EQUITABLE
AND IT'S ALREADY IN YOUR DATA
SET YOU HAVE PREJUDICE INSERTED
ON THE WAY THE DATA IS COLLECTED
AND RATED.
AND WE NEED TO BE PROACTIVE TO
ENSURE THE DATA DOES NOT WE DO
NOT PERPETUATE IT AND IT'S BEEN
RELEVANT GOING THROUGH THE ABC
WHERE WE HAVE SURVEYS FOR
FAMILIES, PARENTS FROM UNDER
REPRESENTED GROUPS WHERE THE WAY
THEY RESPOND IS DIFFERENT.
THE WAY THEY INTERPRET THE
QUESTION IS DIFFERENT.
BUT IT IS RATED AS IF IT WERE
HOME GENEOUS.
THIS RESULTS IN BASICALLY DATA
THAT CAN BE PREJUDICE LIKE AND
DISTORTS THE REALITY.
THIS IS GOING TO BE RELEVANT FOR
THE ABC GOING FORWARD.
I DON'T THINK IN GENERAL IN
SURVEYS THERE'S BEEN AWARENESS
AND REALIZING WHAT MAY BE A
SURVEY OBTAINED IN WHITE PEOPLE
MAY NOT NECESSARILY PERTAIN TO
ANOTHER ONE.
>>THANK YOU FOR THE TALK WHICH
WAS SO COMPREHENSIVE AND
DISHEARTENING WATCHING THE
NUMBERS GO UP.
IT'S DISSPIRITING BUT IT DOES
SPUR US ON TO THINK OF WAYS TO
ADDRESS THE PROBLEM IN A
MULTI-PRONGED WAY AND CONSIDER
THE RESEARCH QUESTIONS TO
SURFACE NEW KNOWLEDGE.
THE PRACTICE AND DESCRIBER
COMMUNITY IS VERY DYNAMIC AS YOU
POINT OUT WITH THE CHANGES.
WITH THE COMPREHENSIVE
APPROPRIATIONS ACT WE SAW BOTH
THE ACT WHICH ON ONE HAND LIFT
THE EX-WAIVER REQUIREMENT
FEDERALLY AND LIFTED THE CAPS
BUT AS YOU POINT OUT WE DON'T
KNOW WHAT STATES WILL DO AND IT
WILL BE A PATCH WORK.
SIMULTANEOUSLY WE DON'T KNOW
WHAT THE EDUCATIONAL
REQUIREMENTS WILL BE AND IN THE
FAST WE HAD A FUNDED PROGRAM
THROUGH THE DATA ORGANIZATION SO
EIGHT HOUR TRAININGS WERE GRATIS
AND WE SIMULTANEOUSLY HAVE THE
ENDING OF THE PUBLIC HEALTH
EMERGENCY WHICH NOW CALLED INTO
QUESTION WHETHER WE'D BE ABLE TO
ISSUE BUPRENORPHINE WITHOUT AN
IN-PERSON VISIT AND THE WHOLE
IDEA OF BEING ABLE TO DO THAT
EXTEND
EXTENDED PLACES WITH SOMEBODY
CANNOT ACCESS SOMEBODY LIVE.
IT'S ABOUT TO HAPPEN IN A
THREE -- MONTH IT'S ALL CHANGED.
SO NONE OF US KNOW HOW THIS WILL
PLAY OUT.
WHAT PART WILL BE GOOD AND IT'S
A RIPE OPPORTUNITY TO STUDY AND
CONSIDER STUDYING IMPLEMENTATION
STRATEGIES AND HOW THOSE MIGHT
HAVE IMPACT OF INTERVENTION
STRATEGIES BECAUSE IT BLENDS
INTO PREVENTION.
WE KNOW WE HAVE MANY MISSED
OPPORTUNITIES AS PEOPLE HAVE
TOUCH POINTS WITH THE HEALTH
CARE SYSTEM.
THEY'RE NEVER SCREENED I'M SORRY
BUT IT'S RARE THEY'RE SCREENED
WITH PEDIATRICS OR OB AND IN THE
HEALTH SYSTEM.
IF YOU TALK TO PATIENTS YOU'LL
FIND THEY HAD THEIR ACTUAL
EXAMINE AND NO ONE TALKS TO THEM
WITH THE USE OF DRUGS.
RESEARCH THAT IMPLEMENTS THAT
KIND OF TOUCH POINTS AND LOOK AT
PREVENTIONS/EARLY INTERVENTION
OR CASE FINDING WITHIN THE
HEALTH CARE SYSTEM.
THAT DOESN'T HAPPEN.
IN TERMS OF RETENTION, SAMHSA
PRODUCED A DOCUMENT FROM 2015 TO
2019 LOOKING AT RACIAL AND
ETHNIC DIFFERENCES AND DIVIDED
IT BY GENDER ACROSS ALL
SUBSTANCES AND BOTH USE DISORDER
AND ACCESS TO TREATMENT.
THE VARIABILITY BY RACE,
ETHNICITY AND GENDER IS
STRIKING.
AGAIN, FOR US TO RESEARCH WHAT'S
MOST EFFECTIVE, PROGRAMS THAT
ACTUALLY LOOK AT CULTURALLY
SENSITIVE AND INTERVENTION
STRATEGIES BECAUSE IT'S NOT
GOING TO BE THE SAME IN
DIFFERENT POPULATIONS.
IT'S NOT.
THOSE THREE AREAS ARE RIPE FOR
RESEARCH.
ALL THIS IS GOING ON WHILE WE
WATCH THE NUMBERS TICK UP.
IT'S INCREDIBLY DISHEARTENING TO
SEE THAT.
AND THERE'S DIFFERENT PARTS OF
THE COUNTRY PILLS AVAILABLE FOR
YOUNG AND OLDER PEOPLE ARE
TAKING AND THERE ARE PEOPLE
USING NOT KNOWING THEY'RE ABOUT
TO I HAVE TAINTED DRUG AND YOUNG
PEOPLE ARE DYING AND AS FAR AS A
PUBLIC HEALTH INTERVENTION WHAT
SHOULD WE BE DOING?
SHOULD WE BE UTILIZING TEST
STRIPS?
SHOULD THEY BE DISPENSED WITH
NALOXONE AND THOSE INTERVENTIONS
FROM A PUBLIC HEALTH STANDPOINT
WE NEED THE ABILITY TO STUDY AND
KNOW WHETHER WE'RE BEING
EFFECTIVE.
THOSE ARE SOME OF MY THOUGHTS IN
RESPOND TO YOUR EXCELLENT
PRESENTATION.
>>WE'RE FUNDING PROJECTS AND
UNDERSTANDING HOW THE CHANGES IN
BUPRENORPHINE WILL BE
IMPLEMENTED BY THE STATE.
THIS IS AN AREA THAT'S NEW.
FOR THE OTHERS, YES, ONE OF THE
ONES AND FACILITATE THE AREAS OF
HEALTH CARE SYSTEM.
WE HAVE IT.
AND THE STRUCTURE COULD ADD
PREVENTION.
THAT'S ONE OF THE ONES WE'RE
VERY MUCH LAUNCHES PRODUCTS
ACROSS THE CLINICAL TRIALS
NETWORK AND SEEKING
OPPORTUNITIES THROUGH MODELS
THAT CAN FACILITATE.
I AGREE 100%.
I BROUGHT UP THE ISSUE OF
BUPRENORPHINE TO GET RESEARCHERS
IN THE FIELD WITH THAT EXPERTISE
TO START TO LOOK INTO IT.
>>YOU ARE NOT MUTED BUT I
CANNOT HEAR YOU.
>>SORRY ABOUT THAT.
I ALSO WANTED TO THANK NORRA --
NORA FOR HER PRESENTATION AND
THE ABC STUDIES YOU REVIEWED AND
THEY'RE LANDMARK STUDIES AND
THINKING OF THEM TOGETHER NOT
JUST IN THE SCOPE OF THE DATA
THEY HAVE PRODUCED BECAUSE ABC
HAS BECOME A MODEL AS SOMEONE
FROM THE GENETICS WORLD THE
AVAILABILITY OF DATA FOR YOUNG
INVESTIGATORS TO LAUNCH THEIR
CAREERS HAS BEEN EXTRAORDINARY
TO THE FIELD.
AND THE AFFECT OF PRENATAL
EXPOSURE ON CHILD DEVELOPMENT
GOING FORWARD TO THE CHILDREN
MATURING INTO ADULTS WHO
THEMSELVES HAVE FAMILIES AND
UNDERSTANDING THAT TRY -- TRIAD
AND BRINGING IT BACK AND THERE'S
AN OPPORTUNITY TO UNDERSTAND THE
EARLIEST EXPOSURES OR RISK
FACTORS MAY BE FOR CHILDHOOD AND
ADOLESCENT SUBSTANCE USE WHICH
MANY POINTED OUT ARE ON THE
INCREASE.
I WAS WONDERING IF THERE ARE
POSSIBILITIES AS WE LEARN MORE
ABOUT PRENATAL USE TO THINK OF
PREVENTION, EDUCATION.
HOW CAN WE INFORM OUR PREGNANT
MOTHERS ABOUT THE POTENTIAL
CONSEQUENCES AND HAZARDS OF
USING IN THIS CASE MARIJUANA
DURING PREGNANCY AND WHAT YOUR
THOUGHTS WERE ABOUT THAT.
>>WHY WE LAUNCHED ABC AND THE
URGENCY TO UNDERSTAND MARIJUANA
IN A STUDY LONGITUDINAL AND WITH
HIV AND WHILE THERE'S ATTENTION
AS THERE SHOULD BE ON THE
AFFECTS OF ALCOHOL ON PREGNANCY
THERE'S LESS ATTENTION FOR
MARIJUANA.
YET WE KNOW THE CONSUMPTION HAS
INCREASED FOURFOLD OVER SIX,
EIGHT YEARS IN WOMEN AND YOU SEE
ADVERTISEMENT.
FOR US TO HAVE CREDIBILITY WE
NEED TO SHOW OBJECTIVE EVIDENCE
WHY YOU SHOULD NOT CONSUME
MARIJUANA.
AND ONE COULD MAKE AN ARGUMENT
ONE WAY OR ANOTHER REGARDLESS OF
THAT MY PERSPECTIVE WHEN IT
COMES TO PREGNANCY IS WHILE
WE'RE COLLECTING THE EVIDENCE
THERE'S SUFFICIENT DATA ALREADY
TO SUGGEST IT COULD BE HARMFUL
SO IT'S BETTER TO BE CAREFUL AND
RECOMMEND NO CONSUMPTION OF THE
DRUG.
THE RISKS ARE HIGH.
YOU HAVE DATA THAT GIVES CAUSE
FOR CONCERN AND EDUCATING THE
PUBLIC IS CRUCIAL AND GIVING
CLEAR-CUT OBJECTIVE DATA THAT
CAN BE UTILIZED TO EDUCATE THE
PUBLIC AND TO GUIDE POLICIES.
AND MINIMIZE RISKS.
>>I DON'T SEE ANY OTHER RAISED
HANDS.
ANY OTHER QUESTIONS?
COMMENTS?
>>GREAT UPDATE.
>>OUR NEXT PRESENTATION IS
GOING TO BE BY AMY NEWMAN WHO
WILL TALK ABOUT THE NIDA IRP AND
GIVE AN OVERVIEW A SAMPLE OF
WHAT IS HAPPENING IN THE IRP BUT
SHOULD BE INFORMATIVE AND
ENJOYABLE.
>>THANK YOU FOR GIVING ME A
CHANCE TO TELL COUNCIL WHAT IS
HOT AT THE IRP.
>>YOU'RE STILL NOT SHOWING THE
RIGHT SCREEN.
>>THANK YOU.
THANK YOU.
I WANT TO START WITH WHOER AND
OUR MISSION TO ADVANCE SCIENCE
ON THE CAUSES AND CONSEQUENCES
OF DRUG ABUSE AND ADDICTION AND
APPLY THAT KNOWLEDGE TO IMPROVE
INDIVIDUAL AND PUBLIC HEALTH.
WE'RE LOCATED IN BALTIMORE.
WE'RE ON A JOHNS HOPKINS CAMPUS
WHICH MEANS WE'RE NOT ON THE
BETHESDA CAMPUS WHERE THE REST
OF THE NIH RESIDES.
THE CHALLENGE OF THAT IS THOUGH
MORE THAN 40% OF OUR BUDGET GOES
TO THE NIH, WE DON'T HAVE ACCESS
TO MUCH OF THE RESOURCES ON THE
BETHESDA CAMPUS.
FOR EXAMPLE, WE HAVE OUR OWN
PHARMACEU
PHARMACY AND CLINIC AND EXPENSES
ASSOCIATED WITH THOSE.
WE LOOK TO MECHANISMS AND
CIRCUITRY AND UNDERSTAND
UNDERLYING SUBSTANCE USE
DISORDER WITH THE AIM OF
TRANSLATING THESE FINDINGS INTO
IMPROVEMENTS IN PREVENTION AND
TREATMENT.
WE'RE A TRAINING INSTITUTION.
WE ARE DEDICATED TO PROVIDING
THE BEST MENTORING AND TRAINING
OPPORTUNITIES FOR TRAINEES TO
ADVANCE THEIR CAREERS AND
PROMOTING A COLLEGIAL CULTURE
AND I HOPE THE REST OF THE
DISCUSSION AND PRESENTATION
YOU'LL SEE EXAMPLES OF THAT.
WE HAD THE CHALLENGE OF COVID
AND WAS APPOINTED SCIENTIFIC
DIRECTOR OF 2020.
I HAD THE OPPORTUNITY AS BEING
THE ACTING SD FOR TWO YEARS
BEFORE THAT EVERYTHING HAS
HAPPENED UNDER THE CHALLENGE OF
COVID IN OUR BACKGROUND.
MY VISION IS OUTSTANDING SCIENCE
DIRECTED TOWARDS SUBSTANCE USE
DISORDER WITH AN EMPHASIS ON
ADDICTION MEDICINE AND
NEUROSCIENCE AND NEURO IMAGING,
PHYSIOLOGY AND DEVELOPMENTS OF
NEW TREATMENT MODALITY.
WE'RE ALSO FOCUSSED ON THE
DEVELOPMENT OF NEW TECHNOLOGIES,
NEW BEHAVIORAL MODELS, NEW DRUGS
AND TREATMENTS AND THE HALLMARK
OF THE IRP IS WE ENGAGE IN
LONG-TERM AND HIGH-RISK PROJECTS
WITH AN EMPHASIS ON
COLLABORATIVE AND TEAM SCIENCE.
FOR COLOR THESE IN BLACK ARE
WHAT WE ALWAYS HAD AND IN PURPLE
ARE THINGS INITIATED IN THE LAST
FEW YEARS.
AS YOU SAW EARLIER TODAY WE HAVE
A STRONG SCIENTIFIC COUNCIL AND
OUR TENURE TRACK INVESTIGATORS
MUST BE REVIEWED EVERY FOUR
YEARS THOUGH WE CAN BE REVIEWED
IN LESS TIME THAN THAT.
BECAUSE I'M REFLECTING WHOLE
BRANCHES OF THE SAME TIME AND
WE'RE STILL IN THE PROCESS OF
DOING THAT, SOME MAY BE REVIEWED
IN SHORTER PERIODS AND SOME HAVE
TO BE REVIEWED IN FOUR YEARS.
SOMETIMES YOU'LL SEE A MIX UP IN
WHO'S BEING REVIEWED BUT
NONETHELESS EVERYONE GETS
REVIEWED EVERY FOUR YEARS.
IN ADDITION TO THE CRITERIA WE
REVIEWED ON, WE ADDED A
DIVERSITY INCLUSION,
ACCESSIBILITY AND EQUITY SUPPORT
PIECE TO OUR INTERVIEW.
IT TURNS OUT I DIDN'T ASK
PERMISSION BUT TURNED OUT LATER
WE WERE THE FIRST INSTITUTE TO
DO THAT AND I WAS THEN ASKED TO
LEAD A GROUP OF SCIENTIFIC
DIRECTORS TO CREATE THAT
VERBIAGE FOR ALL NIH INTRAMURAL
PROGRAMS AND HAD THE NEW GRANT
ARE BRANCH REVIEWS AND I USE
THEM AS AN ADVISORY COUNCIL.
IT'S IMPORTANT THEY BE REVIEWED
EVERY FOUR YEARS ON THEIR
LEADERSHIP TO BE SURE WE HAVE
THE STRONGEST LEADERSHIP WE CAN
WITHIN THE INTRAMURAL PROGRAM
AND THAT IS AN NIH-WIDE CHANGE.
ONE OF THE THINGS I FOCUSSED
ATTENTION ON IS BUILDING OUR
CLINICAL PORTFOLIO.
WE HAVE FOUR CLINICAL TENURE
TRACK INVESTIGATORS AND
REINVENTING THE OFFICE OF THE
CLINICAL DIRECTOR TO PROVIDE THE
BEST SUPPORT FOR OUR CLINICAL
PORTFOLIO.
WE ALSO HAVE NEW LEADERSHIP IN
OUR SCIENTIFIC COMPUTING AND
I.T. SUPPORT AND EVERYBODY'S
GENERATING A LOT OF DATA.
WE DON'T ALL KNOW HOW TO STORE
IT AND MANAGE IT AND ANALYZE IT
AND SO IT REQUIRES A GREAT DEAL
OF EFFORT IN THIS REALM.
FINALLY WE'RE DEDICATED TO
ADDICTION SCIENCE AT THE
INTRAMURAL PROGRAM.
THIS SANE ORGANIZATIONAL CHART.
I WANT TO SHOW YOU ARE HOUSED IN
THE BRANCHES AND IN THE LAST
COUPLE YEARS THESE ARE ALL THE
CHANGES WE'VE MADE.
AND THERE WERE GROUPS IN THE
WRONG PLACE TO SERVE THE WHOLE
INSTITUTE.
IMPLEMENTING THE CHANGES MEANS
WE NOW HAVE A MEAN, CLEAN
MACHINE THAT DOES RESEARCH THAT
WE CAN DO BETTER THAN EVER WITH
THE CHANGES THAT WE HAVE
IMPLEMENTED AND CONTINUE TO
IMPLEMENT.
I ALSO AM VERY DEDICATED NOT
ONLY TO SUPPORTING ALL OUR
PRINCIPLE INVESTIGATORS BUT
GROWING THE NEXT GENERATION OF
INVESTIGATORS.
THESE GRANT ARROWS INDICATE THE
FOUR TENURE TRACK INVESTIGATORS
BROUGHT THROUGH TO TENURE.
THESE.
[LISTING NAMES]
THEY'RE NEWLY TENURED
INVESTIGATES AT THE IRP.
THE CHANGES WILL GIVE US A GREAT
LAUNCHING PAD TO NOT ONLY DO THE
GREAT WORK WE'VE BEEN DOING BUT
EVEN BETTER IN THE FUTURE.
WE STARTED OUT WITH DEVELOPING
OR STARTING THE ADDICTION
MEDICINES BRANCH AND WE HAVE TWO
INVESTIGATORS THAT WORK WITH
THEM.
WE HIRED A NEW TENURE TRACK
INVESTIGATOR IN THE NEUROIMAGING
BRANCH.
THIS WAS UPON THE RETIREMENT OF
ELLIOT STEIN AND NOW THE NEW
NEUROIMAGING CORPS WE CAN OPEN
IT UP TO SCIENTISTS ACROSS THE
PROGRAM AND WE HAVE A CORE LED
SERVICES BASIC AND PRE CLINICAL
SCIENTISTS AS WELL AS OUR
CLINICAL RESEARCHERS.
WE'RE REINVENTING THE OFFICE OF
THE CLINICAL DIRECTOR.
WE HAVE A CLINICAL DIRECTOR
SEARCH WHICH I HOPE WILL CON
INCLUDE WITH A DIRECTOR IN 2023.
AND IMPORTANTLY AND HAVE TO
STRENGTHEN OUR PARTNERSHIP WITH
NCATS WHICH HAS THE CAPABLE TO
TRANSLATE MEDICINES TO THE CL
CLINIC AND PHARMA WITHOUT PHARMA
WE CAN CURE IN RATS AND MONKEYS
BUT WE NEED TO GET IT IN HUMAN
PATIENTS.
AN EXAMPLE OF THIS WORK IS A
COMPOUND FROM ANY LAB THAT'S A
CLINICAL CANDIDATE FOR THE
TREATMENT OF OPIOID USE
DISORDER.
WE DISCOVERED THIS AS A HIGHLY
SELECTIVE D3 RECEPTOR ANTAGONIST
TO PREVENT OR TREAT OPIOID USE
DISORDER.
IN PARTNERSHIP WITH NCATS WHO
RECEIVED FUEL MONEY WE HAVE
DEVELOPED THIS TOWARD AN IND.
IN NOVEMBER WE HAD AN FDA
PRE-IND WRITTEN REVIEW AND
THERE'S BEEN WORK TO GET TO THIS
STAGE.
WE HAVE SO FAR SURVIVED THE
VALLEY OF DEATH.
WE HOPE WE CONTINUE AND THAT WE
WILL BE SUCCESSFUL IN GETTING
THIS INTO CLINICAL TRIALS AND
HELPING FOR A CORPORATE PARTNER
WORKING WITH US AND DOING THIS.
WE HAVE TO HAVE TO CONTINUE AND
I APPOINTED MORALE AS OUR
ASSOCIATE DIRECTOR FOR
TECHNOLOGY AND DIRECTS OUR THREE
TECHNOLOGY CORES AND INITIATED A
TECHNOLOGY DEVELOPMENT
INITIATIVE WHICH IS INCLUDING
MANY OF OUR INVESTIGATORS AND
TRAINEES IN LEARNING MORE ABOUT
TECHNOLOGY DEVELOPMENT.
AND AN EXAMPLE OF THE WORK DONE
IS THIS COOL 3-D RECONSTRUCTION
OF SYNAPTIC MARKERS WE COLLECT
IMAGES AND RECONSTRUCT THE
IMAGES INTO THREE DIMENSION AND
IDENTIFY MARKERS AND SO FORTH SO
THEY CAN BE REALLY GET DEEP INTO
UNDERSTANDING HOW CIRCUITS WORK
AND HOW THEY'RE AFFECTED BY
SUBSTANCE USE AND THERE'S 3-D
RESTRICTION AND THERE'S
ELECTROMICROSCOPE IMAGES AND THE
CONSTRUCTION SHOWS ONE AXON
TERMINAL ESTABLISHED A SYMMETRIC
SYNAPSE ON ANOTHER DENDRITE.
THIS WORK IS BEING USED BY A
NUMBER OF LABORATORIES BUT THIS
IS AN EXAMPLE AND THE GLU
GLUTAMATERGIC NEURONS WERE
AFFECTED AND WE HAVE AN
NEUROIMAGING RESEARCH BRANCH AND
WORK ON PHOTO MAGNETIC
STIMULATION ON RODENTS AND THIS
WORK IS THING TO TO BE
TRANSLATED TO HUMAN TMS STUDIES.
AND THIS IS A LEADER IN
DEVELOPING BEHAVIORAL MODEL FOR
SUBSTANCE USE DISORDER AND
OTHERS AS YOU CAN SEE IN THE
CO-AUTHOR LINE HAVE BEEN WORKING
ON AN OPIOID RECEPTOR KNOCK IN
RAT AND PUBLISHED A PAPER
SHOWING THE AFFECT OF SELECT
LESIONS IN THE RECEPTORS FROM
HEROIN ON MALES AND FEMALES.
THESE ARE A COUPLE EXAMPLES OF
THIS TECHNOLOGY WE'RE USING TO
DO OUR SCIENCE.
IT'S NOT JUST US.
AND WE'RE DOING TRANS NIH
SCIENCE BY WORKING WITH OTHER
GROUPS AND OTHER INSTITUTES.
ONE OF THE THINGS I'VE BEEN A
GREAT ADVOCATE FOR THE CENTER
FOR COMPULSIVE BEHAVIORS.
THIS IS SOMETHING SET UP BY AND
THIS INVOLVES 10 INSTITUTES AND
FELLOWS THAT PUT IN COMPETITIVE
APPLICATIONS.
TYPICALLY WITH PROJECTS THAT GO
ACROSS INSTITUTES AND GET
FUNDING FOR THEIR OPPORTUNITY TO
SHARE THEIR RESEARCH IN MONTHLY
MEETINGS AND AN ANNUAL RETREAT.
IT'S A TERRIFIC PROGRAM AND OUR
P.I.s BENEFIT GREATLY FROM IT.
YOU HEARD FROM INVESTIGATORS
THAT NEED HELP IN HANDLING BIG
DATA.
AND WE HAVE ADVANCED TO WORK
WITH A WELL ESTABLISHED PROGRAM
AT THE NIH AND HAVE TERRIFIC
INTERACTION TO HELP US WITH
THOSE DATA ANALYSIS.
WE STARTED A CLINICAL
INTERACTION WITH NIDDK USING
RODE CAP FOR THEIR MEDICAL
RECORDS AND HAVE SIX NEW
SECONDARY APPOINTMENTS WITH
P.I.s FROM NIAAA, NIMH AND
NINDS.
AND OPEN UP THE OPPORTUNITY FOR
TRANS-NIH RESEARCH AND THESE ARE
ADJUNCT FACULTY AND NOT COSTING
ME MONEY AND IMPROVE THE
DEMOGRAPHIC AND RICHNESS OF THE
WORK AND CAN CO-MENTOR TRAINING
AND HELPING KNIGHT AB TO BE A
STRONGER INSTITUTE WITHOUT
HIRING OUR OWN FACULTY WHICH IS
NOT PHYSICALLY POSSIBLE.
AND WE HAVE A NUMBER OF
INVESTIGATORS THAT JOINED
APPOINTME
APPOINTMENTS AND THEY SHOWED
THERE'S POTENTIAL AS A THERAPY
FOR ALCOHOL USE DISORDERS USING
ANIMAL AND RODENT STUDIES AND WE
HAD AN NDC HIGHLIGHT OF THEM
RECENTLY MANY OF US HAD THE
OPPORTUNITY TO SEE.
AND THERE'S A NEWLY TENURED
PRINCIPLE INVESTIGATOR IN THE
NEUROLOGICAL INSTITUTE AND
ADJUNCT APPOINTEE AND INTERESTED
IN TRANSMISSION OF DOPAMINE AND
PATCH CLAMP AXONS IN MOUSE MAINS
AND WITH RHESUS MACAQUES THEY
CONTACTED US BECAUSE THIS IS A
HIGHLY SELECTIVE DOPAMINE LIGAND
AND THEY WERE ABLE TO SHOW
PHYSIOLOGICALLY THEY BEHAVE
SIMILAR TO THOSE IN MICE
SUGGESTING A SPECIES TRANSLATION
OF THE WORK THAT THEY WERE DOING
I LIKE IT BRAG ABOUT MY FOLKS.
AND JEFF SCHAUMBAUM BECAME A
DISTINGUISHED INVESTIGATOR BUT
THERE'S ONLY 50 AT THE NIH AND
ONLY COME UP A FEW YEARS AND
THIS OPPORTUNITY CAME UP IN
2020.
WE PUT IN AN APPLICATION FOR
JEFF AND BECAME OUR FIRST NIH
DISTINGUISHED INVESTIGATOR.
AND OUR NEW TENURE TRACK
INVESTIGATORS BECAME AN NIH
DISTINGUISHED SCHOLAR.
THIS DIFFERS IN DIRECTED TOWARD
TENURE TRACK INVESTIGATORS.
AND GIVES A COHORT OF TENURE
TRACK INVESTIGATORS TO WORK WITH
AND LEARN HOW TO BETTER DO
SCIENCE AT THE NIH INTRAMURAL
PROGRAM AND WE HAVE ALL WON THE
PRESTIGIOUS MINING FOR AWARD.
AND LORENZO WAS A WINNER AND WE
HAVE ANOTHER PIONEER AWARD
WINNER.
WE HAVE NUMEROUS BED TO BEDSIDE
AWARD AND MANY RECEIVED K99 AND
GET THE FARE AWARD A COMPETITIVE
TRAVEL AWARD ACROSS THE NIH.
SINCE 2020 OUR P.I.s HAVE
RECEIVED COUNCIL REVIEWS AND
SCORES 1 OF 2 OUT OF NINE AND
ARE LEADERS IN DEI INITIATIVES.
WE'RE HIGHLY PUBLISHED AND
HIGHLY SIGHTED.
THE DATA WERE GIVEN TO ME BY MY
GOOD FRIEND AND WE SHARE
BUILDINGS WITH THEM.
SENT ME THE DATA AND SAID YOU'LL
LIKE TO SEE THIS AND IT TURNS
OUT AND THIS IS ACROSS
INSTITUTES WITH AT LEAST 200
MILLION OR MORE PER FIVE YEARS.
AT LEAST $40 MILLION A YEAR PER
YEAR OVER FIVE YEARS EACH BAR
REPRESENTS AN INTRAMURAL PROGRAM
AND YOU'RE LOOKING AT
PUBLICATIONS PER MILLION DOLLARS
PER YEAR ACROSS INSTITUTES AND
WE WERE A
ABOVE THAT OVER FOUR AND WERE
NUMBER ONE ACROSS ALL INSTITUTES
PER $100 MILLION.
IMPORTANTLY, IT'S NOT JUST THAT
WE PUBLIC ALL OF PAPERS BUT IN
THE 10% MOST CITED PUBLICATIONS.
ADDICTION SCIENCE IS NOT ONE OF
THE BIGGER ONES AT THE NIH.
WE'RE COMPETING WITH CANCER AND
AGING AND COVID AND SO FORTH.
IT'S TERRIFIC DETE AND DATA THAT
IS GOING TO BE A CHALLENGE WE'LL
CONTINUE TO MEET.
BEING THE TERRIFIC INSTITUTE
WITHIN THE INTRAMURAL PROGRAM
ONE THING I'VE BEEN COMMITTED TO
IS STRENGTHENING OUR CULTURE AND
PERSONNEL THROUGH DIVERSITY AND
INCLUSION.
I ASKED YEKA TO BE MY DIRECTOR
IN ADDITION TO RUNNING HER OWN
LABORATORY AND SHE'S REVAMPED
OUR FELLOWSHIP FOR DIVERSITY AND
RESEARCH PROGRAM.
THIS IS A PROGRAM WE'VE HAD OVER
10 YEARS THAT NEEDED TWEAKING
AND DEVELOPED A FANTASTIC
PROGRAM FOR POST-BACS WHO APPLY
THE PROGRAM AND IT'S COMPETITIVE
AND THEY NEED TO APPLY WITHIN
THE INTRAMURAL PROGRAM AND
THERE'S ALSO A STRONG MANDATE
FOR THE P.I.s TO HAVE STRONG
MENTORSHIP.
SHE MEETS WITH THEM EVERY MONTH
AND HAVE ACTIVITIES INCLUDING
WORKING ON THE COMMUNITY
OUTREACH GROUP WHICH IS A NEW WE
JUST STARTED AND DR. BRENDA
CURTIS IS LEADING THAT.
IN ADDITION WE HAVE A NEW
RESEARCH PROGRAM WITH THE
UNIVERSITY OF MARYLAND BALTIMORE
COUNTY.
THIS IS SOMETHING NORA HELPED US
SET UP WORKING ON MATH AND
SCIENCE THROUGH A LOCAL
UNIVERSITY.
STRONG S.T.E.M. AND COME IN AND
WORK IN OUR LABS FIVE OR TEN
HOURS PER WEEK DURING THE SCHOOL
YEAR AND IN THE SUMMER AND THIS
HAS BEEN HIGHLY SUCCESSFUL FOR
THEM AND HAVE AN INCLUSION LED
DIVERSITY, EQUITY, INCLUSION AND
ACCESSIBILITY COMMITTEE THAT
DOES GREAT THINGS IN
COMMUNICATIONS AND HAS SPEAKERS
FOR OUR ENTIRE INSTITUTE.
WE HAVE A WOMEN'S SCIENTIST
ADVISORY WE SHARE WITH NIA AND
HAVE THE FRIENDS AND FELLOWS
GROUP.
WE WANT THE COMMUNITY TO KNOW US
AND TAKE ADVANTAGE OF THE THE
WORK WE DO AND STARTED TO HAVE
BOOTHS AT PLACES LIKE THE
BALTIMORE ZOO AND HEALTH FAIRS
AND WE HAD OUR OWN HEALTH FAIR
IN BALTIMORE IN THE PARKING LOT
OF OUR INSTITUTE.
WE HAD MANY VENDORS FROM ACROSS
THE STATE THAT CAME IN DIFFERENT
ASPECTS OF HEALTH.
WE DID NALOXONE TRAINING AND
MANY OTHER THINGS AND THERE WAS
A FOOD TRUCK AND MUSIC AND IT
WAS FUN AND WE'LL DO IT AGAIN.
IT'S THE BEGINNING OF GETTING
OUR BALTIMORE COMMUNITY TO KNOW
WE'RE HERE, KNOW WHAT WE DO AND
TO PARTICIPATE IN OUR STUDIES IF
THEY CAN.
WE'VE DEVELOPED A FANTASTIC
COLLABORATION WITH STEVE THOMAS.
THERE'S FUNDING THROUGH THE
UNIVERSITY OF MARYLAND CENTER
FOR HEALTH EQUITY AND HE'S
CREATED THIS THING CALLED THE
HEALTH ADVOCATES IN REACH AND
RESEARCH CAMPAIGN WHERE HE GOES
TO LOCAL BARBERSHOPS AND MEETS
WITH PEOPLE AND TALKS ABOUT
THEIR HEALTH AND TALKS ABOUT
BLOOD PRESSURE AND TEMPERATURE
AND TALKS ABOUT THINGS AND WE'RE
JOINING STEVE TO GET INTO THE
COMMUNITY, TALKING ABOUT
SUBSTANCE USE DISORDER,
PREVENTION, TREATMENT AND ALL
THOSE THINGS.
I THINK THIS IS JUST THE
BEGINNING BUT I THINK WE HAVE A
GREAT THING GOING HERE.
I HOPE IT WILL IMPROVE OUR
STANDING IN THE COMMUNITY AND WE
CONTINUE TO BE A BEACON OF
INNOVATIVE RESEARCH WITH
EMPHASIS ON THE NEUROSCIENCE OF
ADDICTION AND OUR GOAL IS TO
TRANSLATE INTO PREVENTION AND
TREATMENT AND NEW MEDICATION
TREATMENT DEVELOPMENT BY
STRENGTHENING OUR CLINICAL
PORTFOLIO AND WORKING ON
DIVERSIFYING STAFF AND PROVIDING
MENTORSHIP AND TRAINING TO
STRENGTHEN OUR RESEARCH PROGRAM
AND THE ADDICTION RESEARCH
COMMUNITY GLOBALLY.
I HOPE I'VE CONVINCED YOU WE'RE
FULLY ENGAGED IN OUR RESEARCH
AND COMMUNITY OUTREACH AND SEE
OUR WEBSITE BECAUSE THERE'S MORE
TO COME.
THANKS SO MUCH FOR THE
OPPORTUNITY AND I AM HAPPY TO
TRY TO ANSWER ANY QUESTIONS YOU
MIGHT HAVE.
AND WITH FUCHSIA ON YOUR SLIDES
I LIKE THEM MORE.
>>I CAN'T HELP IT.
LOOK AT MY OUTFIT.
>>THANK YOU FOR THE
PRESENTATION AND GREAT OVERVIEW.
HOW DO YOU TRANSLATE NIDA'S
PRIORITIES AND WE SHAPE INTEREST
TOWARDS THOSE GOALS.
HOW DO YOU INTERACT WITH THOSE
PRIORITIES ON A DAY TO DAY BASIS
AND THEN TRANSLATE THAT WITH
YOUR INVESTIGATORS AND THE
DIFFERENT DIVISIONS TO ALSO BE
BRING THE INTRAMURAL WORK TO THE
CRISES AND EMERGENCIES AND
PRIORITIES WE'RE ALL FACING.
>>IT'S COMMUNICATION BETWEEN ME
AND NIDA AND SENIOR STAFF AND
LEARNING THAT LEVEL AND TALKING
TO COLLABORATORS AND THE PEOPLE
I WORK WITH AND TALKING WITH
EACH ONE OF MY AND WE'RE ALWAYS
SAYING WHAT ARE THE PRIORITIES.
THE OTHER THING I TRIED TO DO
BEST I CAN IS CONTINUE TO BRING
NEW YOUNG THINKERS AND PEOPLE IN
THE FOLD.
WHAT CAN THEY CONTRIBUTE
ULTIMATELY WE DO THE BEST WE
CAN.
WE HAVE A TREMENDOUS RESOURCE AT
THE INTRAMURAL PROGRAM AND WE
HAVE THIS PRIVILEGE TO BE ABLE
TO TAKE ON HIGH RISK AND
LONG-TERM PROJECTS THAT ARE IN
THE PRIORITIES OF NIDA.
I'M DISCOURAGED WITH THE NUMBERS
AND WHEN YOU SEE THE NUMBERS
CONTINUE TO CLIMB IT'S LIKE WHAT
THE HECK ARE WE DOING AND I'M A
MEDICINAL CHEMIST AND HAVE BEEN
MAKING MOLECULES TO TREAT
COCAINE AND OPIOID USE DISORDER
FOR YEARS AND WE FIGURED IT OUT
IN RATS AND IT WORK BUT GETTING
IT TO PEOPLE IS SUCH A
TREMENDOUS CHALLENGE AND REALLY
TRYING TO ENGAGE PHARMA TO HELP
US BECAUSE WE DO GREAT RESEARCH
BUT WE DON'T DO WHAT FAPHARMA A
NEED THEM TO WORK WITH US TO TRY
TO TAKE THESE MEDICATIONS AND
TREATMENTS INTO THE PEOPLE WHO
NEED THEM.
I MAD A MEET ABOUT TECHNOLOGY
TRANSFER AND HOW IT MARKET AND
MARKET AND ENCOURAGE THEM TO GET
COMPANIES TO TAKE THE WORK
FORWARD.
>>DO YOU FIND COMPANIES ARE
LESS SHY OR CAPABLE IN TERMS OF
COMING FORWARD TO COLLABORATE
CINCINNATI THE SHUT DOWN.
>>I THINK THE PEOPLE MAY HAVE A
BETTER ANSWER BECAUSE THEY HAVE
MORE INTERACTIONS THAN I DO BUT
ESSENTIALLY LITTLE COMPANIES
COME IN AND LICENSE OUR
TECHNOLOGIES AND RUN OUT OF
MONEY BEFORE THEY DO ANYTHING.
WE HAD A COMPANY WORKING WITH US
AND JUST DROPPED OUT LAST YEAR
AND NOW WE'RE LEFT HOLDING THE
BAG WITH BIG INVESTMENT AND WE
HAVE A BIG PORTFOLIO AND LOOKING
FOR SOMEONE TO TAKE IT ON AND
SEE WHERE IT COMES FROM.
THERE'S MORE SMALL COMPANIES
THAT THINK THEY'RE INTERESTED
BUT IT TAKES A LOT OF MONEY TO
DO THIS AND WE NEED THE BIGGER
COMPANIES WITH THE DEEPER POCKET
TO PAY ATTENTION.
THE OTHER THING I'M TRYING IS
AND THERE ARE COMPANIES
INTERESTED IN SCHIZOPHRENIA AND
THEY HAVE A HUGE MORBIDITY
SUBSTANCE USE DISORDER AND IF WE
GO THAT ANGLE MAYBE WE CAN GET
MORE INTEREST AND THAT'S WHAT
I'M TRYING TO DO.
>>AND IF THE COMPANY ALREADY
WENT THROUGH THE TROUBLE OF
GETTING THE INDICATION, HAVING A
SECONDARY INDICATION THEY
ALREADY HAVE THEIR PRIMARY
INDICATION.
>>THE ADJUNCT IS A GOOD IDEA
AND SOMETHING WE'RE TRYING TO
PROMOTE AS WELL.
>>MAYBE NIDA CAN CONSIDER SOME
BUSINESS DEVELOPMENT FUNCTION OR
EMISSARY WHERE SOMEBODY CAN
REACH OUT AND TALK TO PEOPLE
WITHIN PHARMA THAT MAY HAVE NO
OTHER WAY OF KNOWING ABOUT THE
KINDS OF EFFORTS AND RESEARCH
OPPORTUNITIES THAT THERE ARE.
I CAN TELL YOU FROM MY OWN
EXPERIENCE AND PERSPECTIVE IN MY
COMPANY WE NEVER WOULD HAVE
SUCCEEDED IN GETTING AN FDA
APPROACHED MEDICATION FOR OPIOID
USE DISORDER WITHOUT NIDA AND
THERE'S COMPANIES THAT WOULD
WANT TO PARTNER BUT DON'T KNOW
HOW TO ACCESS.
>>THERE'S HISTORICAL BACKGROUND
THAT HURTS US THAT'S HARD TO
WORK WITH NIH AND IT'S
BUREAUCRATIC BUT IT'S CHANGED A
LOT.
OUR TRANSFER IS 100% BETTER THAN
IT USED TO BE AND ARE DEDICATED
AND AT THE NIH LEVEL THEY'RE
TRYING TO DO WHAT YOU DESCRIBED.
MAYBE THERE'S A WAY TO PARTNER
WITH DTMC TO TARGET OUR PART OF
THE MARKET.
>>IT'S SOUGHT OUT THE VARIOUS
COMPANIES AND IDENTIFY HOW TO
THE POINT THAT IDENTIFY
MOLECULES THEY HAVE AND IT'S
EASIER FOR THEM TO MOVE AND
THERE'S A WAY TO LOOK AT THIS
FOR INSOMNIA IN THE OPIOID USE
DISORDER.
THAT IS SLOWLY COMING ABOUT WITH
PARTNERSHIPS FROM INDUSTRY.
WE'RE STILL WILLING TO PARTNER
FROM BIG INDUSTRY IN SUBSTANCE
USE DISORDER IN THE PAST IS
STILL EXTREMELY LIMITED.
AND WHERE WE'VE BEEN SUCCESSFUL
IS WITH SMALLER COMPANIES BUT
THERE ARE SEVERAL PROJECTS FOR
NEW MOLECULES EXPANDED WITH THE
ADDITION OF THE HEAL DOLLARS.
THE HEAL DOLLAR ALLOWS US TO
CREATE PARTNERSHIPS.
WE'RE DOING IT BUT AS YOU KNOW
THE ISSUE OF DEVELOPING
MEDICATION IS A RISKY BUSINESS
FULL OF THE LIKELIHOOD OF
FAILURE.
TRYING TO MOVE -- AND ONE THING
FOR FAILURE IS THE FACT THAT THE
COMPANIES AND PERCEPTION IN
GENERAL FOR FDA TO APPROVE A
MEDICATION FOR SUBSTANCE USE
DISORDER IS DIFFICULT TO
ACHIEVE.
YOU HAVE TO BE ABSTINENT FOR A
CERTAIN PERIOD OF TIME.
WHEN IN FACT THERE'S LIKELY TO
BE OTHER OUTCOMES.
THIS IS WHERE WE'RE INTERESTED
JOT JUST WITH INDUSTRY BUT TO
FIGURE OUT IF WE CAN ESTABLISH
ALTERNATIVE OUTCOMES TO
INCENTIVIZE INDUSTRY TO JUMP
INTO IT.
THIS IS RELEVANT TO WHAT WE DO
FOR MEDICATION DEVELOPMENT.
>>THAT'S EXCELLENT.
>>THANK YOU FOR THE
PRESENTATION.
I THOUGHT IT WAS FANTASTIC AND
GLAD TO HEAR YOU HAVE A
DEPARTMENT THAT FOCUSES ON
CULTURAL USE.
MY QUESTION TO YOU IN YOUR
VISION HOW DO YOU USE THAT
PARTICULAR DEPARTMENT TO BOLSTER
THE NUMBER OF UNDER SERVED
COMMUNITIES THAT RESEARCH IS
TAKING PLACE BUT ALSO NOT ONLY
THE UNDER SERVES COMMUNITIES BUT
INCLUDING RESEARCHERS REFLECTIVE
OF THOSE COMMUNITIES IN THEIR
RESEARCH?
I THINK THERE'S BEEN A HUGE NEED
FOR THAT.
SOME WE'RE SEEING BUT A LOT OF
IT WE ARE NOT.
>>I AGREE.
I DON'T KNOW I'LL TAKE THAT ON.
AS WELL AS I'D LOVE TO, BECAUSE
WE DON'T REALLY -- THE
DEPARTMENT WE HAVE AN ASSOCIATE
DIRECTOR AND A BUNCH OF P.I..ESE
AND TRAINEES WORKING AT A
DIFFERENT LEVEL.
FROM A TRAINEE STANDPOINT MAKING
NIDA A PLACE PEOPLE WANT TO COME
AND FEEL INCLUDED AND LIKE THEY
CAN CONTRIBUTE AND HAVING A
DEMOGRAPHIC OF FACULTY AND
HAVING THE REPUTATION OF BEING A
GREAT PLACE TO BE AND JUMP OFF
FROM COMING IN AS POST-BACS OR
GRADUATE STUDENTS AND GETTING
INTO FACULTY POSITIONS AND FROM
AND I'M FOCUSES ON THE NEXT
GENERATION AND GETTING THEM
EXCITED ABOUT WHAT WE DO AND GET
THEM OUT DOING WHAT THEY DO IN A
TERRIFIC WAY.
SERVING OUR COMMUNITY IS ANOTHER
BIG CHALLENGE.
AT THE INTRAMURAL PROGRAM IN
BALTIMORE.
WE HAVE A COMMUNITY HERE AND IF
WE CAN REACH THEM AND ONE THING
IN ADDITION TO THE COMMUNITY
OUTREACH WE HAVE A SPEAKERS'
BUREAU AND A NUMBER GAVE TALKS
AND OTHER PEOPLE THROUGHOUT THE
COMMUNITY TO EDUCATE THEM ABOUT
SUBSTANCE USE DISORDERS AND
ABOUT THE WORK WE'RE DOING AND
HOPE WE GET THEM EXCITED ABOUT
PARTICIPATING IN WHATEVER LEVEL
THEY MIGHT BE ABLE TO AND IT'S A
WORK IN PROGRESS AND I'M ALWAYS
OPEN FOR SUGGESTION.
I HAVE A DEDICATED GROUP OF
PEOPLE THAT WANT TO MAKE THIS
HAPPEN BUT WE'RE ALWAYS OPEN FOR
SUGGESTION.
THANK YOU.
>>I'LL REACH OUT TO YOU.
I'M WELL CONNECTED TO THE
COMMUNITY AROUND YOU AND OTHER
COMMUNITIES THAT ARE UNDER
SERVED.
I'LL REACH OUT AND SEE HOW I CAN
HELP.
>>THANK YOU TO THE PEOPLE
WORKING ON THIS BECAUSE I KNOW
THEY'D BE DELIGHTED IN WHAT YOU
HAVE TO SAY AND WORK WITH YOU.
>>THANK YOU FOR ALL YOU DO.
>>THANK YOU.
>>THANKS FOR THE PRESENTATION.
AMY KNOWS THIS FOR YEARS I WAS
AT JOHNS HOPKINS NEXT DOOR TO
WHAT WAS THE OLD IRP.
THE ARC WHEN I GOT THERE AND
OVER THE YEARS I'VE SEEN CHANGES
IN THE INTRAMURAL PROGRAM AND
THERE'S BEEN A METEORIC RISE IN
THE STATURE OF THE SCIENCE
HAPPENING AT THE INTRAMURAL
PROGRAM.
I THINK IT TAKES EVERYBODY TO DO
THAT BUT I THINK YOU'VE BEEN
INCREDIBLY EFFECTIVE AT
ATTRACTING REALLY STELLAR PEOPLE
AND EXCELLENCE TRACT --
ATTRACTS EXCELLENCE.
YOU WANT IT TO BE A PLACE WHERE
PEOPLE WANT TO COME AND DO GREAT
WORK.
I'M THRILLED AND IT'S A NATIONAL
GEM.
YOU'RE TO BE CONGRATULATED AND I
KNOW YOU DIDN'T DO IT YOURSELF
BUT A COMMENT I HAVE IS I'D LOVE
TO HEAR MORE WHAT THE CLINICAL
PROGRAM DOING BECAUSE I DONE
THINK WE HAD A FOCUSSED
PRESENTATION AROUND -- I KNOW
YOU HAD TRANSITION ALSO WITH
FACULTY.
I'D LOVE TO HEAR THAT IF WE CAN
PUT THAT ON A FUTURE MEETING.
>>SHARON THANK YOU.
IT MEANS A LOT TO ME FROM YOU.
I GET GREAT SUPPORT FROM MY
INSTITUTE DIRECTOR AND ALSO THE
CLINICAL PROGRAM IS GOING TO
BE -- EXTEND THE METEOR.
WE'RE STILL WORKING TO GET IT TO
HAPPEN.
WE'VE NEVER HAD SIX CLINICAL
INVESTIGATORS AND FOUR ARE
TENURE PRAC AND THEY'RE ALL HOT.
THEY'RE WORKING HARD.
IT'S NOT EASY TO LEAVE ACADEMIA
AND COME TO THE NIH AND THE
FIRST YEAR OR TWO WAS A LITTLE
TOUGH.
IN ANOTHER YEAR OR TWO WE'LL
HAVE A LOT TO SAY AND PRESENT.
I THINK IT WOULD BE A TERRIFIC
OPPORTUNITY TO HAVE THEM COME
AND SPEAK TO ALL OF YOU AND
WE'LL BRING IT BACK, SHARON.
>>I'LL COME AS A GUEST.
I'D LOVE TO SEE THAT.
THANK YOU, AMY.
>>YOU'RE WELCOME.
>>OKAY.
WE'RE DUE FOR A BREAK UNLESS
THERE'S ANY OTHER URGENT
QUESTIONS.
THAT WAS A GREAT UPDATE THANK
YOU, AMY.
>>THANK YOU FOR YOUR COMMENTS.
SEND ME FEEDBACK.
>>WE'LL BREAK NOW TO 3:30.
>>I'M GOING TO DO THE NEXT
PRESENTATION WHICH IS GOING TO
BE AN UPDATE ON THE DISCUSSIONS
THAT HAPPENED WITH THE MERIT
WORK GROUP.
SO I'M JUST REPRESENTING WHAT
THEY HAVE DISCUSSED AND THOUGHT
ABOUT THIS PROGRAM.
AND HOPEFULLY WE'LL BE ABLE TO
CONTINUE THE DISCUSSION AND IT
WILL BE A RICH DISCUSSION TO
HELP NIDA DECIDE WHERE TO GO
WITH THE PROGRAM.
YOU'LL SEE THE SLIDE SHOWING WHO
IS ON THE WORK GROUP AND MEMBERS
OF THE COUNCIL AND FROM THE
RESEARCH COMMUNITY FROM
DIFFERENT SCIENTIFIC AREAS AND
POINTS IN THEIR CAREER.
AND COUNCIL FOR THE DISCUSSION.
SO THE MERIT AWARD HAS BEEN
AROUND A WHILE.
THE PURPOSE IS TO RECOGNIZE
INVESTIGATORS WHO DEMONSTRATED
AT A HIGH LEVEL COMPETENCE AND
HAVE BEEN PRODUCTIVE AND HAVE
BEEN LEADERS IN THE FIELD AND
HAVE TRANSFORMED THE FIELDS AND
PROVIDES THE INVESTIGATORS WITH
LONG-TERM STABLE SUPPORT SO THEY
CAN GET ANOTHER FOUR OR FIVE
YEARS ADDED ON TO THEIR CURRENT
GRANT DEPENDING ON WHEN THE
MERIT AWARD IS GIVEN.
THE INSTITUTE NOMINATES MERIT
CANDIDATES.
THIS IS NOT SOMETHING PEOPLE
APPLY FOR AND NOMINATIONS ARE
PRESENTED TO COUNCIL FOR
CONSIDERATION AND THE FINAL
SELECTIONS ARE MADE BY THE
INSTITUTE DIRECTOR.
THERE ARE SEVERAL CRITERIA USED
FOR THE MERIT AWARDS INCLUDING
THE FACT THE PERSON HAS TO
PREVIOUS LIZ SERVE AS A P.I. AS
ONE OR MORE
INVESTIGATOR-INITIATED PROJECTS.
THEY'RE NOT EARLY STAGE
INVESTIGATORS TYPICALLY OR NOT
AT ALL.
AND THEY ALSO HAVE TO HAVE THIS
IMPRESSIVE RECORD OF OVER ALL
ACHIEVEMENT AND HAVE TO HAVE AN
EXISTING RO1 OR RO1 EQUIVALENT
IN THE FIFTH PERCENTILE OR
BETTER AND PROVIDE TIME
COMMITMENT OF 15% OR MORE TO THE
GRANT.
THERE'S SEVERAL OTHER CRITERIA
AS WELL.
BACK IN MAY WE STARTED TO HAVE A
DISCUSSION LOOKING AT WHO HAS
GOTTEN THE MERIT AWARD FROM NIDA
FOR A NUMBER OF YEARS WHAT OTHER
INSTITUTES WERE DOING.
AND MERIT STANDS FOR METHOD TO
EXTEND RESEARCH IN TIME.
SOMETHING LIKE THAT.
ANYWAY, RIGHT NOW ABOUT HALF THE
OTHER INSTITUTES AT INSTITUTE
ARE NOT USING THE MERIT AWARD
ANY MORE AND AMONG THE OTHER
HALF SOME HAVE MODIFIED THE
INVESTIGATORS TO WHO THEY GIVE
IT TO INCLUDING THE NATIONAL
CANCER INSTITUTE WHICH GIVES THE
AWARD TO EARLY STAGE
INVESTIGATORS.
WHEN WE EXAMINED WHO RECEIVED
MERIT AWARDS FROM NIDA THERE WAS
A LACK OF GENDER AND RACIAL AND
ETHNIC DIVERSITY AND SCIENTIFIC
AREAS WERE ALSO NOT REPRESENTED.
WE MOSTLY THE AWARDS PENT TO
SCIENTISTS FROM THE BASIC
SCIENCE RESEARCH FIELD AND
CRITERIA CAN ONLY BE MET BY
EXPERIENCED INVESTIGATORS THAT
HAVE A HISTORY OF OUTSTANDING
CONTRIBUTIONS.
THESE INVESTIGATORS ARE ALL
EXCEPTIONAL OUTSTANDING
INVESTIGATORS OVER ALL THEIR
PAPERS TEND TO SHOW BETTER
CITATION RATES THAN OTHER
INVESTIGATORS IN THE FIELD.
THERE'S NO DOUBT THEY'RE HIGHLY
QUALIFIED AND ACCOMPLISHED
PEOPLE.
THE MERIT AWARD DOES NOT GIVES
THEM A BREAK FROM THE HAVE
THEIVE REQUIREMENTS OF
SUBMITTING ANOTHER GRANT AND
GETTING IT REVIEWED.
THESE ARE ALSO INVESTIGATORS WHO
ARE GOING TO CONTINUE TO GET
GRANT SUPPORT LIKELY IF THEY
WANT TO CONTINUE TO DO THAT.
AFTER THE DISCUSSION AND THE
CLEAR INDICATION THERE WAS A
LACK OF DIVERSITY WE DECIDED TO
CONVENE A WORK GROUP TO FUTURE
DISCUSS THE MERIT AWARDS AT NIDA
AND PROVIDE RECOMMENDATIONS TO
THE COUNCIL.
THE CHARGE IS COUNCIL CONVENE A
WORK GROUP TO ADVISE ON THE
FUTURE OF THESE AND THE WORK
GROUP WOULD LOOK AT THE CURRENT
CRITERIA AND DECIDE IF WE SHOULD
GET RID OF THE MERIT AWARD ALL
TOGETHER OR FIND OTHER CRITERIA.
THAT'S WHAT I'M PRESENTING TODAY
THE RESULTS OF THE DISCUSSION.
OF THE PEOPLE SHOWN ON THE SLIDE
WE HAVE A PEOPLE ON COUNCIL AND
NOT ON COUNCIL.
WHO ARE MERIT AWARDEES AND ALSO
ON OUR COUNCIL CURRENTLY NOT
PART OF THE GROUP.
WE HAD A DISCUSSION ON THE
VALUES WE NEED TO HOLD UP FOR
THE MERIT AWARDS.
CONTINUING THEM ALTOGETHER OR
CHANGE THE ELIGIBILITY OR CREATE
AN ADDITIONAL AWARD.
WE DISCUSSED THE NOMINATION
PROCESS.
THE NOMINATIONS COME FROM NIDA
STAFF IF AN INVESTIGATOR MEETS A
CERTAIN CRITERIA.
IT COULD BE DONE IN A DIFFERENT
WAY.
THERE WAS A SUGGESTION TO HAVE
EXTRAMURAL REVIEWERS BUT
EXTRAMURAL REVIEWERS HAVE
ALREADY REVIEWED THE GRANTS.
I DON'T KNOW IF THAT'S THE WAY
WE'D WANT TO GO.
WE CAN LOOK AT CAREER STAGE.
WE CAN RESTRICT THESE TO EARLY
STAGE INVESTIGATORS OR P.I.s AT
THE STAGE OF GETTING THEIR FIRST
RO1 RENEWAL AND THIS COULD BE A
STRONG BOOST EARLY IN THEIR
CAREER POTENTIALLY.
WE CAN CHANGE THE PERCENTILE
REQUIREMENT AND USE CUT-OFF
CRITERIA FOR SCIENTIFIC TOPIC OR
INVESTIGATOR CHARACTERISTICS.
ANOTHER CRITERIA IS THEY DON'T
GO TO MULTI-P.I. RO1s AND NOW
WE'RE MOVING IN THE DIRECTION OF
TEAM SCIENCE AND THE NEED FOR
DIFFERENT EXPERTISE AND
EXPERIENCE IT MAY NOT MAKE SENSE
TO RESTRICT THIS TO ONLY
INDIVIDUAL INVESTIGATORS.
WE LOOKED TO SEE APART FROM THE
CRITERIA OF HAVING THE
REQUIREMENT FOR PRIOR RO1 AND
LOOKED AT HOW MANY EARLY STAGE
INVESTIGATORS WOULD HAVE
QUALIFIED WITH THE EXISTING
CRITERIA AND IT WAS LITTLE OR
NONE.
WE DECIDED TO LOOK BETWEEN 2017
AND 2021 FOR INVESTIGATORS ESIs
AND MET THE CRITERIA OF HAVING
RO1 OR RO1 EQUIVALENT GRANT
USING DIFFERENT PERCENTILE
CUTOFFS.
IF YOU DID THE 1-10% CUT-OFF WE
HAD 12ESIs AND TO QUALIFY AND I
WILL MENTION WE DON'T GIVE THAT
MANY IN A YEAR.
WE USUALLY ONLY ONLY GIVE ONE OR
THREE OR FOUR AND A POOL TO WORK
WITH IF THIS IS THE DIRECTION WE
WANT TO GO IN.
WE ALSO TALKED ABOUT THE IDEA OF
HAVING A ONE TO ONE RATIO OF
MERIT AWARDS TO ESI AND SENIOR
SCIENTISTS.
AND THEY COULD DERIVE FROM
GETTING MERIT AWARDS.
WE COULD HAVE PRIOR SCORES FOR
ESIs THAN FOR SENIOR SCIENTISTS.
THE DISCUSSION AROUND SINGLE
VERSUS MULTI-P.I. RESEARCH
AWARDS WAS APART FROM THE FACT
MULTI-P.I. RESEARCH IS BECOMING
MORE COMMON IN MOST FIELDS OF
SCIENCE WE A DISCUSSION WHETHER
OR NOT THERE WERE CERTAIN AREAS
OF SCIENCE WHERE THAT WAS MORE
LIKELY TO OCCUR.
WE DID AN ANALYSIS LOOKING BY
DIVISION AT THE SINGLE VERSUS
MULTI P.I. AWARD BETWEEN FISCAL
YEAR '17 AND '21.
THERE ARE MORE SINGLE P.I.
AWARDS THAN MULTI-P.I. AWARDS
BUT THE PATTERN WAS NOT
DIFFERENT BASED ON THE
DIVISIONS.
THIS IS NOT WHAT WE WERE
ACCEPTING BUT THAT'S WHAT THE
DATA ARE.
ON THE OTHER HAND, WE'RE SEEING
QUITE A FEW MULTI-P.I. AWARDS.
THE NUMBERS ARE NOT QUITE HALF
BUT THEY'RE CLOSE TO HALF FOR
DMB AND OTHERS.
WE DON'T HAVE A STRONG BIAS
BETWEEN SINGLE AND
MULTI-RESEARCH AWARDS BUT
THEY'RE BECOMING MORE COMMON
ACROSS NIDA.
THESE WERE RECOMMENDATIONS THE
WORK GROUP DISCUSSED.
IN GENERAL THEY WERE FAVORABLE
ABOUT CONTINUING THE MERIT AWARD
AND WERE SUGGESTING SOME
MODIFICATION.
SOME WERE TO EXPAND BEYOND THE
RO1 EQUIVALENTS AND CONSIDER
EQUITY FOR THE CRITERIA AND
PRIORITIZE AS HEALTH EQUITY AS A
CRITERION AND THE RENEWAL PHASE
IS THE EXTENSION OF THE GRANT
THE TIME WHEN INVESTIGATORS ARE
NOT HAVING TO REAPPLY FOR
ANOTHER AWARD.
AT THAT POINT WE COULD REQUIRE A
DEMONSTRATION OF EITHER
PROMOTING OR ADVANCING EQUITY IN
THE FIELD.
FOR SOMEBODY WHO WAS A LESS
EXPERIENCED INVESTIGATOR THE
EXTENSION COULD REQUIRE A PLAN
TO ENHANCE DIVERSE PERSPECTIVES.
WE HADN'T TALKED ABOUT THIS VERY
MUCH AT COUNCIL.
IT'S SOMETHING WE ARE NOW ADDING
TO MORE AND MORE OF OUR FUNDING
OPPORTUNITY ANNOUNCEMENTS BUT
PEDP REQUIRES A DESCRIPTION WHAT
THEY'LL DO TO BRING MORE
DIVERSITY TO THE RESEARCH AND
PART OF THE SCORING CRITERIA.
AND THERE WEREN'T MULTI-P.I.
AWARDS AND THAT'S A FUNCTION OF
SOMETHING OLDER THAT BE NIH'S
WAY OF DOING THINGS AND THE
DURATION OF THE AWARD.
IT'S A MAXIMUM OF 10 YEARS.
SOME OTHER I.C.s OFFER
SEVEN-YEAR AWARDS SUCH AS NINDS
AND THERE WAS AN ARGUMENT MADE
TO KEEP THE MAXIMUM BECAUSE IT
ALLOWS INVESTIGATORS TO TAKE
SCIENTIFIC RISK OR CHANGE
DIRECTI
DIRECTIONS I THINK IF WE DECIDE
TO MAKE CHANGES IN THE PROGRAM I
THINK WE NEED TO THINK OF WAYS
WE'LL WANT TO EVALUATE IT.
ARE WE REACHING MORE DIVERSE
RESEARCHERS AND EXPANDING TO
OTHER FIELD BEYOND BASIC SCIENCE
FIELD.
BASIC SCIENCE IS NOT THE ONLY
AREA WHERE WE FUNDED MERIT
AWARDEES BUT IT DOES TEND TO
DOMINATE WHEN WE SHOWED THE
ORIGINAL DATA BACK IN MAY.
IF WE DO GIVE A MERIT TO ECI TO
THEIR FIRST COMPETING RENEWAL WE
CAN EVALUATE HOW IT AFFECTS
THEIR CAREER AND ACADEMIC
ADVANCEMENT, THEIR CONTINUED
GRANT SUPPORT AND WHETHER WE CAN
SEE EVIDENCE OF MORE
INNOVATIONAL RISK TAKING THOSE
THAT RECEIVE THE AWARD.
THIS IS THE LAST SLIDE.
I WANT TO OPEN THIS UP TO OTHER
MEMBERS OF THE GROUP AND COUNCIL
AND INCORPORATE FEEDBACK FROM
KANSAS AND CONSIDER RERISING --
REVISING THE MERIT AWARD
CRITERIA AND WE'LL SHARE THAT
WITH THE WORK GROUP MEMBERS AND
COUNCIL AND FINALIZE THE
CRITERIA AND PUBLICLY POST THIS
FOR AWARENESS.
THAT'S ANOTHER ISSUE THAT CAME
UP IN THE DISCUSSION.
MANY PEOPLE WERE NOT AWARE OF
WHAT THE CRITERIA WERE FOR THE
MERIT AWARDS.
WE'LL POST THE CRITERIA AND WE
CAN GET RID OF THE SLIDES.
FOR PEOPLE PART OF THE WORK
GROUP, PLEASE JUMP IN AND IF
THERE'S THINGS I MISSED OR
MISCHARACTERIZED OR HAD OTHER
ADDITIONS YOU WANTED TO MAKE.
THIS ALSO GOES FOR THE PEOPLE
WHO WERE INVITED TO PARTICIPATE
IN THE OPEN SESSION THAT ARE NOT
ON COUNCIL BUT PART OF THE
WORKING GROUP.
>>MY IMPRESSION IS IT DOESN'T
COST NIDA VERY MUCH BECAUSE
THEY'RE LIKELY TO GET THEIR
GRANTS REVIEWED ANYWAY.
IT DOESN'T IMPACT THE BUDGET THE
WAY YOU MIGHT THINK WHEN GIVEN
I
IN AN AWARD LIKE THIS OR BEING
INVOLVED IN MAYBE MORE RISKY
THINGS.
IT MAY LEVERAGE THE TIME THE
INVESTIGATOR HAS TO ACCOMPLISH
OTHER GOALS NIDA MIGHT HAVE.
I USED MY TIME TO TAKE MORE OF
AN ACTIVE ROLE IN MENTORING AND
REACHING OUT TO YOUNGER
INVESTIGATORS AND SPENDING TIME
WORKING WITH YOUNG INVESTIGATORS
INSTEAD OF KEEPING MY NOSE TO
THE GRANT WRITING GRIND STONE
AND TAKE RISK IN TERMS OF
PROFESSIONAL DEVELOPMENT FOR
OTHERS.
THAT COULD BE OPERATIONALIZED IN
THE PROCESS SAYING WHAT IS YOUR
PLAN TO USE YOUR POSITION AS A
MERITORIOUS NIDA INVESTIGATOR TO
BRING UP OTHER INDIVIDUALS WHO
YOU HAVE INTERACTIONS WITH.
AND IT DIDN'T INCREASE THE WAY
IT NORMALLY WOULD WITH THE
RENEWAL.
IT MIGHT HAVE SAVED NIDA MONEY
AND USING AN INVESTIGATOR TO USE
THAT FREE TIME SOMEBODY CARES
ABOUT WOULD BE A WONDERFUL
OPPORTUNITY.
>>I DON'T THINK IT'S A COST
ISSUE BUT A QUESTION OF ARE WE
FURTHERING AN ELITISM IN WHICH
WE CONTINUE TO SORT OF GIVE MORE
TO THE PEOPLE WHO ALREADY HAVE A
LOT.
IT'S NOT A COST ISSUE AND I
ACTUALLY DON'T THINK THE
DISCUSSION REALLY FOCUSSED ON
LET'S GET RID OF IT FOR THE
SENIOR INVESTIGATORS BECAUSE
IT'S NOT WORTH WHILE.
IT'S MORE SHOULD WE EXPAND IT
AND GIVE IT AND IF WE DO EXPAND
IT WHAT ARE THE CRITERIA WE
SHOULD USE IN ORDER TO EXPAND
IT.
I HAVE A RESPONSE THAT THE COST
YOU ALL NOTICED, WHICH IS THIS
SORT OF FURTHERING ELITISM THE
FACT IT WAS SO WHITE AND SO MALE
IN TERMS OF THE AWARDEES THAT
SEEMS REALLY SIGNIFICANT LIKE A
MISTAKE THAT'S BEEN MADE THAT
MUST BE CORRECTED KNOW.
ONE THING I DON'T THINK I
UNDERSTOOD FROM THE PRESENTATION
IS HOW THE SELECTION CRITERIA
WOULD WORK IS THERE A GUARANTEE
YOU'RE FIXING THE PROBLEM RATHER
THAN FIXING THE PROBLEM.
JUNIOR FOLKS COULD NOW APPLY BUT
THE CRITERIA PRIVILEGES THE MOST
ESTABLISHED AND SUCCESSFUL FOLKS
THAT WOULDN'T GIVE US REASON TO
THINK IT'S ACTUALLY GOING TO BE
SUCCESSFUL AT FIXING THE
PROBLEM.
WONDERING ABOUT WHAT CRITERIA
AND DO YOU HOLD THAT BACK FOR
EARLY RESEARCHERS THERE'S A
NUMBER FOR SENIOR AND SOME FOR
JUNIOR OR WHAT.
>>ALL THAT IS ON THE TABLE.
THAT WAS WHAT WAS PRESENTED BUT
I DO THINK THAT'S THE SUGGESTION
OF HAVING AN EQUAL NUMBER EARLY
STAGE INVESTIGATORS.
IT DOESN'T NECESSARILY ENSURE
DIVERSITY AND EARLY STAGE
INVESTIGATORS COMING FROM THE
BEST AND MOST RESOURCED
INSTITUTIONS.
IT'S PART OF THE CRITERIA ON
RESEARCH WHERE WE CAN EXPAND ON
DIVERSITY OR REQUIREMENT FOR
PEDP.
THAT MAY BE A WAY TO START.
I DON'T THINK THERE'S ANY SIMPLE
ANSWER HOW TO DO THIS.
I THINK WE'RE OPEN TO CHANGING
THE CRITERIA.
WE DON'T HAVE TO AND WE DON'T
HAVE TO AND WE CAN -- WE CAN
HAVE TWO SEPARATE AWARDS AND ONE
BE MERIT.
I ALSO WANT TO CLARIFY, PEOPLE
DON'T APPLY FOR THESE AWARDS.
>>I HAVE TREMENDOUSLY
BENEFITTED IN THE SAME WAY HOW
IT WAS OUTLINED BEFORE.
AND IT REWARDS PEOPLE LONG IN
THE FIELD DOING A PERSISTENT
LINE OF RESEARCH AND COMMITTED
TO WHAT THEY'RE DOING.
IT HAS ITS MERITS.
WHAT I'M SHOCKED BY IS YOU DON'T
GET A DIVERSE POPULATION AND
YOUNG INVESTIGATORS.
THAT'S THE PROBLEM.
IF YOU WOULD HAVE THEM YOU WOULD
CONSIDER THOSE FOUR MERIT AWARD
AND THAT'S NOT THE CASE.
UNLESS YOU CHANGE THE CRITERIA
ABOUT THE PERCENTILE, THEN IT
BECOMES PROBLEMATIC AND IT'S
UNCLEAR HOW EXPANDING IT TO
YOUNGER INVESTIGATORS AND OTHER
THINGS IS GOING TO MAKE AN
IMPACT.
WHAT TRAVIS SAID FOR ME THINKING
WHY PEOPLE ARE NOT SCORING IN A
BETTER PERCENTILE IN EARLY
DIVERSE OR IN THEIR CAREER IS A
PROBLEM PROBLEM WE KNOW THAT
EXISTS AND AT THE CORE OF THE
PROBLEM.
I'M NOT SURE WHAT YOU OUTLINED
IS GOING TO CHANGE THAT CORE
ISSUE.
>>I WANT TO POINT OUT IF THOSE
NUMBERS I SHOWED QUICKLY ON THE
BAR GRAPH, THAT WAS A FOUR-YEAR
PERIOD AND STILL DIDN'T HAVE A
HUGE NUMBER OF ESIs THAT FELL IN
THE CRITERIA OF THE FIRST OF
15%.
IT'S NOT GOING TO OPEN IT UP
DRAMATICALLY.
IT DOESN'T ADDRESS THE ISSUES
YOU BROUGHT UP WHICH IS HOW DO
WE MAKE SURE THAT WE ARE HOW DO
WE IMPROVE THE SCORES OF PEOPLE
NOT SCORING SO WELL AND MAKE
SURE THEY -- I DON'T KNOW ALL
THE REASONS.
THERE'S PROBABLY MANY REASONS
FOR THAT.
>>OR IS THERE BIAS?
>>ABSOLUTELY.
>>THANK YOU, THIS BRINGS UP THE
ISSUE OF HOW BIAS GETS EMBEDDED
SOMETIMES.
ONE QUESTION I HAD IS IT'S NOT
CLEAR -- IS IT AUTOMATIC IF
SOMEONE HAS A GRANT BELOW 5% THE
MAIM IS BROUGHT UP OR ANOTHER
STEP IN THE MIDDLE?
HOW DOES THE BIAS CREEP IN?
BY UNDERSTANDING IS THAT AFTER
THAT YOU NEED TO BE NOMINATED
AND YOU HAVE THE MAJORITY AND
MALE AND THAT KIND OF WOKS WORK
AND DID THE GROUP TALK ABOUT
MOVING AWAY FROM THAT?
I WANTED TO BUILD ON WHAT
TRAVIS WAS SAYING BECAUSE IT'S
NOT CLEAR THE PROCESS OF HOW IT
WAS DONE WAS OUTLINED TO THINK
ABOUT AND FOR YOU TO REVIEW AND
POTENTIALLY CHANGE.
>>ONCE THE MINIMUM REQUIREMENTS
ARE MET, THE DIVISIONS WILL DO A
REVIEW OF ANY INVESTIGATORS
WITHIN THE FUNDING PERIOD THAT
COULD BE PUT FORWARD AS A MERIT
AWARDEE.
THEY'LL MAKE SUGGESTIONS.
AND I THINK I'D HAVE TO ASK THE
DIVISION DIRECTORS HOW TO DO
THAT AND I MAY BE A BIAS BUT
MAYBE NOT WHAT OTHER ISSUES
AROUND WHAT THE ACTUAL SCORES
ARE.
I'M NOT SURE PARTICULARLY
BECAUSE DMV GIVES THE MAJORITY
OF MERIT AWARDS BUT PERHAPS SHE
CAN TALK A LITTLE BIT MORE ABOUT
THE CRITERIA YOU USE.
>>WE HAVE GONE BY THE 5
PERCENTILE WE SAY WHO MEETS THE
CRITERIA AND LOOK AT THEM AND
DISCUSS THEM.
THERE AREN'T THAT MANY.
THERE'S FEW AND WE DISCUSS THEM
AS A GROUP AND PUT FORWARD
INDIVIDUALS.
SINCE I'VE BEEN THERE I FEEL
WE'VE BEEN SENSITIVE TO THE
ISSUE THERE'S BEEN FEW ER FEMALS
AND MINORITIES.
ONE OF THE THINGS THAT HAS COME
UP IS WITH JUNIOR ADVOCATORS SO
THOSE -- USUALLY YOU LOOK AT
SOMEONE ESTABLISHED AND IN THE
FIELD A LONG TIME AND CONSI
CONSISTENTLY SUCCESSFUL AND
THERE'S INVESTIGATORS THAT DON'T
REACH THAT.
SO THAT'S WHERE WE HAVE HAD THE
MOST DISCUSSION.
THAT'S ESSENTIALLY WHY THE
COMMITTEE WAS FORMED.
WE HAD QUESTIONS AND WHETHER THE
INDIVIDUALS SERVED WOULD BE
BETTER SERVED BY THEM THERE.
>>
>>I WAS A MEMBER OF THE WORK
GROUP AND CURRENT MERIT AWARDEE.
LIKE OTHERS I HAVE GREATLY
BENEFITTED FROM THE AWARD SUSAN
DID A NICE JOB SUMMARIZING AND
IT'S NOT JUST YOU HAVE TO SCORE
UNDER THE FIFTH PERCENTILE BUT
ALSO HAVE TO HAVE A RO1.
THAT OFF THE BAT TAKES OFF THE
EARLY STAGE INVESTIGATORS
BECAUSE BY DEFINITION ONCE YOU
HAVE AN RO1 YOU'RE NOT AN EARLY
STAGE INVESTIGATOR.
I GOT ONE AT MY SECOND RO1 AND
MID-CAREER AND DECENTLY EARLY
BUT NOT THE NORM.
WHEN WE WERE LOOKING AT THE DATA
IT'S NOT JUST DIVERSITY OR TYPE
OF PERSON THAT GETS THE AWARDS
BUT DIVERSITY OF SCIENCE AS
WELL.
THERE'S A HEAVY EMPHASIS ON
BIOLOGICAL FUNDING AND I WAS
TOLD I WAS THE FIRST
IMPLEMENTATION SCIENTIST TO GET
A MERIT AWARD AND I THINK IN
LARGE PART IS BECAUSE THESE ARE
BIG STUDIES, MULTI-SITES AND ALL
MY OTHERS IN MY PORTFOLIO ARE
MPI.
I WAS FORTUNATE TO GET A MERIT
ON MY ONLY SOLE P.I. GRANT.
THINGS WHERE MAKING THINGS
FLEXIBLE IN MY LINE OF WORK
THERE'S MANY MECHANISMS THAT ARE
RO1 EQUIVALENT AND THOSE CHANGES
COULD HAVE IMPACT ON DIVERSITY
OF SCIENCE.
>>WE HAVE TWO PEOPLE NAMED
ANNA.
>>A QUICK QUESTION RELATED TO
THE MPI COMPONENT.
FIRST I WANT TO THANK THE WORK
GROUP FOR CONSIDERING THAT.
FOR THOSE WHO DO TEAM SCIENCE'S
A GAME CHANGER IN TERMS OF
MAKING THAT AN OPPORTUNITY FOR
ELIGIBILITY.
WONDERING IF THE WORK GROUP HAD
ADVICE FOR WHETHER A MULTIPLE
P.I. PROGRAM WHETHER THEY
CONSIDER ALL THE P.I. OR EACH
P.I. IN COMBINATION WITH THEIR
FUNDING HISTORIES AND HOW THAT
IF THE COMMITTEE HAD
RECOMMENDATIONS FOR THAT?
>>THE ONE INSTITUTE THAT DOES
DO MULTI-P.I. AWARDS WILL ONLY
IF THEY THINK ALL THE P.I.s
WOULD MERIT A MERIT.
CAN'T IMAGINE A ONE AWARD AND
NOT THE OTHERS.
IT SEEMS LIKE THAT WOULD BE HARD
TO MAKE TO DISTINGUISH IN
DETERMINING THEIR CONTRIBUTIONS
TO THE FIELD.
>>I REMEMBER WITH MY MENTOR
RECEIVED ONE AND IT WAS A NICE
HONOR AND LOOKING AT IT NOW FROM
THE PERSPECTIVE OF 20 OR MORE
YEARS LATER AND THINKING WHAT
PROBLEM IT IS WE'RE TRYING TO
ADDRESS.
ARE WE MANY ARE MERIT AWARD
WINNERS AND SHOULD BE BUT IS THE
GOAL TO TRY TO BRING ALONG
PEOPLE WHO ARE EARLY OR DIVERSE
AND IF THAT'S THE GOAL, THAT MAY
BE A SEPARATE AWARD THE THING TO
THINK ABOUT IS THE TIME THE
AWARDS WERE STARTED MAYBE THERE
WASN'T THOUGHT WHETHER IT WOULD
INCREASE THE GAP BETWEEN PEOPLE
WHO ALREADY HAVE, WILL GET AND
WILL BE RENEWED BECAUSE THEY'RE
ALREADY SUPERIOR SCIENTISTS AND
SUPERIOR HMMS AND THEY'LL DO
PRETTY WELL.
THERE'S AN ISSUE IN OUR FIELD
WITH PEOPLE STRUGGLING TO GET
THEIR FORCEDD RO1.
WE HAVE A CHALLENGIING FIELD FO
PEOPLE TO GET OFF THE GROUND AND
GET LAUNCHED AND STAY LAUNCHED.
THERE'S A LOT OF THOSE PEOPLE
AND WONDERING HOW WE CAN
ENCOURAGE PEOPLE IN THE FIELD
AND KEEP THEM IN THE FIELD
KNOWING MANY PEOPLE ON THIS
PROPERLY RECOGNIZED FOR BEING
WONDERFUL WILL MAKE IT BUT WHAT
ABOUT THE LARGER GROUP OF PEOPLE
I GUESS MAKE UP THE BULK OF THE
FIELD WHO DID NOT GET A FIFTH
PERCENTILE OF THAT PARTICULAR
DAY OF THE PEER REVIEW.
YOU CAN GO FROM A FIFTH
PERCENTILE AND IT DOESN'T GET
THE FIFTH PERCENTILE AND NOW
WHERE ARE YOU?
ARE YOU LESS MERITORIOUS OR
SUBJECT TO THE VAGARIES OF PEER
REVIEW WE KNOW ABOUT?
SEEMS LIKE THERE'S TWO ISSUES.
ONE IS ABOUT INCREASE THE GAP
AND BRINGING PEOPLE ALONG AND
NEED GRANTEES AND PEOPLE WORKING
IN THE FIELD.
IT SEEMS THERE'S TWO IRISHES.
AND THEY PUB THEM IN THE
DIRECTION WHERE MAYBE THE
INTENTIONAL AWARD IS GREAT AND
ENABLED PEOPLE TO HAVE TIME AND
THAT'S WONDERFUL BUT WHERE ARE
WE NOW IN THIS FIELD?
>>THIS ISN'T CLEARLY THE LAUNCH
MECHANISM.
THERE'S OTHERS.
THE FOCUS ON ESIs IS IMPORTANT.
YOU LOSE YOUR NEW INVESTIGATOR
STATUS ONCE YOU HAD AN RO1 AND
MAINTAIN YOUR STATUS FOR THE
FIRST 10 YEARS POST GRADUATE.
I THINK HAVING AN EMPHASIS ON
THE ESI THE PEOPLE WHO ARE STILL
RELATIVELY EARLY BECAUSE THEY
GET IN THE PIPELINE BUT DON'T
STAY IN IT AND CAN SOLVE THAT
AND POTENTIALLY LOOKING AT THE
PERCENTILE MAYBE CONSIDERING
FLEXIBILITY BECAUSE I ENVISION
WHEN SOMEONE GETS THEIR FIRST
RO1 THEY'RE AN EARLY
INVESTIGATOR.
IT'S POSSIBLE THEY HAVE NOT AS
GREAT SCORES AS COUNTERPARTS.
WE DON'T WANT TO MAKE THEM
INELIGIBLE.
THIS IS A DIFFERENT KIND OF
MECHANISM AND I THINK THE FOCUS
ON ESI AND THE DIVERSITY STUFF
WOULD BETTER ALIGN WITH THE
INTENT OF THE MECHANISM.
>>YOU DO LOSE YOUR ESI STATUS
WHEN YOU GET AN RO1.
IT'S FOR SOMEBODY NEW TO NIH.
AND NEVER GOT ONE BEFORE AND
ONCE THEY GET IT THEY WOULD LOSE
THE NEW AWARD STATUS.
>>THAT'S NOT WHAT'S ON THE NIH
WEBSITE AND WHAT I'M TOLD IN MY
REVIEW PANEL.
THE NEW INVESTIGATOR NEVER HAD
AN RO1 AND 10 YEARS AND YOU'RE
SAYING IT'S NOT ACCURATE.
I PUT IT IN THE CHAT.
>>I GUESS I'M ON THE WRONG
SITE.
SORRY, I DIDN'T REALIZE THAT.
>>MANY ARE NOT NEW
INVESTIGATORS.
THEY'RE JUST NEW TO NIH
INVESTIGATORS.
>>THAT'S NEW TO ME, SORRY.
>>WE'RE GOING OVER TIME.
I'LL ASK NORA WOULD YOU WANT TO
ASK IVONNE TO UPDATE AT THE NEXT
COUNCIL MEETING TO CONTINUE
LONGER OR STOP AFTER THE NEXT
COMMENT?
I'D LIKE TO HEAR FROM COUNCIL
MEMBERS BECAUSE IT'S IMPORTANT
TO KEEP ON THE DISCUSSION AND
THEN ASK IVAN TO POST POINT TO
NEXT COUNCIL.
ALTERNATIVELY, IF YOU THINK WE
DISCUSSED IT SUFFICIENTLY, WE
CAN HAVE IVAN GO AHEAD.
WHY DON'T I POSE THE QUESTION TO
ALL OF YOU WHO WANT TO CONTINUE
THE DISCUSSION, PLEASE RAISE
YOUR HAND.
WE HAVE A SENSE OF WHAT YOU'RE
PREFERENCES ARE.
>>IT'S OKAY WE POSTPONE THIS
FOR NEXT COUNCIL IN MAY.
>>I'D LIKE A LITTLE BIT MORE
TIME BECAUSE I'VE BEEN
STRUGGLING THE WHOLE DAY TRYING
TO THINK I WAS GOING TO SAY IN
15 MINUTES ALLOCATED.
I WANT TO ANSWER ONE BURNING
QUESTION ABOUT THE INDUSTRY
INVOLVEMENT.
WE HAVE MANY PROJECTS WITH
INDUSTRY AND A PERSON IN CHARGE
OF INDUSTRY RELATIONS DAVE WHITE
TO REPLACE DAVE McCAN.
AND NOW HE'S IN CHARGE OF
INDUSTRY RELATIONS AND WE HAVE
SOMEONE IN CHARGE OF REGULATORY
SUPPORT AND WHO SUPPORTED
SUPPORT TO AMY IS MARTHA
DeSANTIS.
>>BECAUSE OF YOUR FLEXIBILITY
WE'LL WORK WITH YOU GIVING YOU
MORE TIME IN MAY.
LET'S GO AHEAD WITH THE
DISCUSSION.
>>DID YOU HAVE ANYTHING ELSE
YOU WANTED TO SAY?
>>I DIDN'T LOWER IT.
WE CAN STILL FOCUS ON PEOPLE
EARLIER IR THIN CAREERS.
WE WANT TO STOP PEOPLE FROM
FALLING OUT OF THE PIPELINE AND
HAVE IT BIASSED IN FAVOR OF MORE
SENIOR AND NOT OLDER BUT THE
EXPERIENCE AND THEY'VE BEEN AT
IT FOR A LONG TIME.
AS THE ABOUT THE STRATEGY TO
MINIMIZE THE BIAS.
THANK YOU.
>>THANK YOU.
IT'S AN IMPORTANT CONVERSATION
IT HAS A LOT TO WITH THE STAY IN
RESEARCH.
IT'S THE NEXT PHASE IN MID ERAND
SENIOR PHASE.
I THINK IT'S IMPORTANT BECAUSE
WE THINK OF THE SUSTAINABILITY
OF THE RESEARCH CAREER AND THINK
OF STRUCTURAL BIASES SOME OF THE
THINGS THE WORK GROUP SUGGESTS
ARE WORTH CONSIDERATION.
IT MAY BE GOOD TO HAVE TWO
CATEGORIES OF THE AWARDS.
ONE THAT'S MORE SENIOR AND ONE
MORE CAREER AND HOW YOU WANT TO
DO THAT MAYBE YOU CHANGE THE
ELIGIBILITY A BIT FOR EACH OF
THOSE SO IT REFLECTS THE
POPULATION YOU'RE TALKING ABOUT.
I THINK THE IDEA OF TRYING TO
FIGURE OUT A WAY TO EXTEND IT TO
MPI GRANTS GIVEN THE SCIENCE IN
OTHER FIELD IS A GOOD ONE AND I
THINK CHARLES SAID IF YOU'RE
GOING TO HAVE ONE OF THESE IS
THERE A WAY TO STRUCTURE THE
CRITERIA ABOUT WHAT YOU EXPECT
FROM IN THE CRITERIA AND
BRINGING UP THE NEXT SCIENTISTS
IN THE FIELD AND WHAT TO EXPECT
FROM AN AWARDEE AND HOPEFULLY IT
WOULD YIELD THOSE OTHER KINDS OF
GOALS.
>>ONE PLACE YOU CAN DO THAT
BECAUSE WE DO A SEPARATE
CONSIDERATION IT'S
ADMINISTRATIVE REVIEW OF THE
EXTENSION OF THE AWARD WHICH IS
THE EXTRA TIME AND WE COULD MAKE
IT A REQUIREMENT BECAUSE THE
INVESTIGATORS HAVE TO SUBMIT
INFORMATION ON WHAT THEY PLAN TO
DO AND THAT COULD BE THE TIME
WHEN IT'S A REQUIREMENT TO GET
THE EXTENSION THE VALUE OF A
MERIT AWARD.
I DON'T THINK IT'D BE DIFFICULT
TO DO.
DENNIS?
CHARLES.
>>MY IMPRESSION TO INCREASE THE
DIVERSITY OF OUR POOL AND THE
MOST IMPACTFUL WAY TO DO THAT IS
PUTTING MORE MONEY IN THE K99
PROCESS.
IDENTIFY INDIVIDUALS AT THE
EARLY STAGE AND MAKE SURE THEY
HAVE A STRONG START.
IF YOU GIVE THEM A K99 AND
INCREASE THE YOU'LL HAVE A BIG
IMPACT AND INDIVIDUALS STARTING
OUT MAY NEED THE EXTRA TIME.
IT'S NOT NECESSARILY STOPPING
TAKING MONEY FROM THIS PROGRAM
AND MAKING IT BETTER FOR SURE IN
THE WAYS YOU OUTLINED BUT
DEVOTING ATTENTION AND RESOURCES
WHERE THE INDIVIDUALS ARE WHO
WILL BECOME THE NEXT SENIOR
INVESTIGATORS REFLECTING THE
DIVERSITY WE WANT.
AND GOING BACK TO THE CRITERIA,
WHEN I REPRESENTED TO WHAT THEY
POSTED I SAID THEY'RE GOING IN
THE WRONG DISTRIBUTION.
THIS IS EXACTLY THE WRONG
DIRECTION TO INCREASE THE
DIVERSITY OF THE AWARDEES.
YOU CAN'T DO WHAT THEY'RE TRYING
TO DO.
IT'S NOT MY SCIENCE BUT MY
EXPERIENCE IS THE BIAS THAT
COMES INTO IDENTIFYING A SCORE
IS THE IMPLICIT BIAS AND WHEN
YOU DEAL WITH IMPLICIT BIASES WE
ALL HAVE, THE ONLY WAY TO GET
RID OF THEM IS TO MAKE THEM
EXPLICIT.
IF YOU SAY, WHAT IS YOUR SENSE
OF THIS PERSON AND SENSE OF THIS
MAKING THE BIASES EXPLICIT AND
NOW COUNTER WITH A SCORE.
IF YOU'RE NARROWING THE APPROACH
AND BOILS DOWN TO THE GUT
REACTION OF THE REVIEWER TOWARDS
THAT PERSON.
IT GETS BUDDIED UP.
THEY ARE CAN'T SEPARATE THAT
FROM THE SCIENTIST AND LOSE
SIGHT OF THE OTHERS AND WHEN
THEY WANT TO FOCUS ON AN
INVESTIGATOR MAYBE THEY'RE NOT
IN AWE OF THEY SUPPORT THEIR
FEELING AND NOT THEIR DATA.
BY IGNORING MAKING BIASES
COMPLICIT AND DILUTING THEM IS
NOT WHAT'S DONE THEY MADE THE
IMPLICIT BIASES EVEN MORE
STRONG.
THAT'S ALL I WANTED TO SAY.
>>I WANT TO MENTION IN THE CHAT
BECAUSE MANY ARE ON THE
VIDEOCAST AND CAN'T SEE THEM AND
ONE WAS A COMMENT BY SARA BECKER
WHICH I THINK IS INTERESTING TO
HAVE THE MERIT AWARD WINNERS AS
PARTICIPATE AS MENTORS IN THE
NIDA SUMMER MENTORSHIP PROGRAM
WHICH IS A CONCRETE SUGGESTION
AND MIGHT ALSO BE HELPFUL IN
TERMS OF DIVERSIFYING A
WORKFORCE.
THE OTHER POINT IS ABOUT THE
MENTORED K AWARD SAYING WE MAY
WANT TO CONSIDER BEYOND THE K99s
AND INCLUDING OTHER AREAS OF THE
SCIENCE LIKE THE K23s MORE
CLINICALLY ORIENTED.
I THINK THIS IS A SEPARATE
DISCUSSION WE HAD AND INCREASED
THE PERCENTAGE OF OUR BUDGET
THAT GO TO K AWARDS.
WE GET GOOD APPLICATIONS AND
IT'S HARD TO MAKE THOSE CHOICES.
I THINK THAT'S A SEPARATE
DISCUSSION AND ONE WORTH
CONSIDERATION.
>>I DON'T THINK I'M HEARING AS
MUCH CONVERSATION AROUND A POINT
ON YOUR SLIDE WHICH IS WHAT IF
WE CONSIDER THE COMMUNITIES WITH
WHICH THE APPLICANT WORKS?
WE KNOW HISTORICALLY THAT
COMMUNITY ENGAGED SCIENCE, CVPR
ISN'T UNDERSTAND OR REVIEWED AND
HAS DIFFERENT METRICS OF
SUCCESS, MAY HAVE
COMMUNITY-BASED INVESTIGATORS
WHO WON'T HAVE A BUNCH OF NIH
AWARDS UNDER THEIR BELT.
THAT'S A MIX UP OF THE GAME
HERE.
IT'S NOT CONFLATING EARLY CAREER
SCIENTISTS WITH THIS MERIT
THING.
IF YOU GET AN RO1 WE KNOW YOUR
PRETTY DANG GOOD.
YOU'RE HITTING THE MARKS OF
RIGOROUS SCIENCE.
I DON'T CARE SO MUCH WHAT
PERCENTAGE OF THE TOP SCORING
BUT WHERE THE MONEY WILL HAVE
IMPACT IN TERMS OF SAVING LIVES.
WE KNOW INEQUITIES ARE KILLING
PEOPLE ON THE GRANDER SCALE.
IF THAT'S WHAT WE ARE TRYING TO
CHANGE WITH A MERIT AWARD THAN
THAT'S WHERE THE MONEY SHOULD
FLOW IN MY OPINION BUT HAVEN'T
HEARD PEOPLE TALK ABOUT THAT SO
HOW DO YOU FEEL ABOUT THAT
PARTICULAR BULLET POINT?
>>WE TALKED ABOUT THE AREAS OF
SCIENCE WE WANT TO SUPPORT AND
DON'T NECESSARILY NEED A
PERCENTILE CUT OFF POINT.
IN FACT THEY AREN'T NECESSARILY
LOOKING AT THAT.
THERE'S MANY WAYS TO GO AND THAT
COULD BE AN AREA.
I
I'M CONCERNED BECAUSE WE HAVE
MANY CONCEPTS TO PRESENT AND
WANT TO MAYBE WANT TO GIVE IT
BACK TO NORA TO SUMMARIZE YOUR
THINKING ON IT.
I DON'T FEEL LIKE WE HAVE A
CONSENSUS YET.
>>WHAT I THINK THERE IS MORE OR
LESS IS THE CONSENSUS IS THAT
IT'S A VALUABLE MECHANISM AND
NIDA SHOULD CONTINUE AND CAN'T
JUSTIFY MERIT AWARDS THAT WILL
BE DIFFEN PREDOMINANTLY TO WHITE
MALES, NOT THAT I HAVE ANYTHING
AGAINST WHITE MALES, WE HAVE
EXTRAORDINARY SCIENTISTS BUT
THERE'S A PORTION OF SCIENTISTS
NEGLECTED AND NOTE CONSIDERED.
.
WE HAVE TO SOLVE THAT PROBLEM
AND NEED TO LOOK AT IF THE MERIT
AWARD IS THE BEST MECHANISM TO
DO THAT AND HOW TO USE THE MERIT
AWARDS TO ENGAGE THEM IN ORDER
THE RENEWAL TO ENSURE THEY'RE
PARTICIPATING AND DIVERSIFY
MINORITY SCIENTISTS.
THOSE ARE ISSUES THE LAST IS
STRAIGHTFORWARD AND IS IT A
MECHANISM WE SHOULD USE TO GIVE
AN OPPORTUNITY TO EARLIER STAGE
INVESTIGATORS INITIATING THEIR
CAREER AND MINORITY OR SHOULD WE
THINK OF ALTERNATIVE ONES?
AS A RESEARCHER THE MERIT AWARD
ITSELF IS A PRESTIGIOUS
MECHANISM.
DO WE GENERATE THE MECHANISMS
THAT WILL BE ASSOCIATED WITH
THAT RECOGNITION THAT MAKES IT
EASIER TO GET RESOURCES AND
SUPPORT.
OR LOOK AT AREAS OF SCIENCE WE
WANT MORE INVESTMENT IN BY YOUNG
INVESTIGATORS.
HOW WE INITIATED THE AWARD
ITS
ITSELF I THINK IT DESERVES
FURTHER CONSIDERATION AND WOULD
LIKE TO HERE ABOUT IT AND LOOK
AT THE SUBJECT MATTER.
I CANNOT GIVE A CLEAR
DETERMINATION OF WHAT WE SHOULD
BE DOING BUT CLEARLY IDENTIFY
WHAT ARE SOME OF THE ACTIONS TO
TAKE TO CREATE A FAIRER
DISTRIBUTION OF RESOURCES
THROUGH THE GRANT MECHANISMS.
>>TO BE CONTINUED.
>>AND WE NEED TO DO HOMEWORK
WITHIN NIDA AND COME BACK TO
COUNCIL IN MAY WITH SOME
DISCUSSIONS.
>>BY THE WAY, THE POINT WAS
TAKEN IN TERMS OF WHERE YOU
BEGIN TO REBALANCE INEQUITIES.
THOSE BEGINNING AWARDS ARE A WAY
OF OPENING UP THE FIELD TO GET
PEOPLE IN THE FIELD THEN YOU CAN
GO FROM THERE.
IT MAY BE A PIECE OF THE
DISCUSSION THAT'S SEPARATE BUT
SEEMS TO BE SOMETHING IMPORTANT
IF THE OVER ALL GOAL IS TO TRY
TO GET THINGS OPEN AND MORE
BALANCED.
>>THERE ARE STILL SOME
QUESTIONS IN THE CHAT BUT I'LL
TRY TO GET BACK TO THEM
SEPARATELY.
OWE THINK WE NEED TO MOVE ON
BECAUSE WE HAVE QUITE A NUMBER
OF CONCEPTS TO HAVE PRESENTED.
SEVERAL ARE FOR CONTRACTS AND
WHEN WE PRESENT THE CONCEPT OR
CONTRACT WE NEED A VOTE ON IT.
FOR THE OTHER CONCEPTS WE'RE
LOOKING FOR FEEDBACK AND INPUT
AND WE'LL GO THROUGH THEM
QUICKLY AND THEY WERE ALL IN THE
ELECTRONIC COUNCIL BOOK BUT
STILL A ONE-PAGER ON THE
CONCEPT.
IF THERE'S ANY YOU WANT US TO
DISCUSS STOP US ALONG THE WAY.
THAT'S WHY WE'RE BRINGING THEM
HERE.
WE HAVE A CONCEPT PRESENTED BY
THE OFFICE OF RESEARCH TRAINING
AND DISPARITIES, ARIA.
>>YES.
ENTITLED NIDA RESEARCH EDUCATION
PROGRAM FOR CLINICAL RESEARCHERS
AND CLINGS FOR FOA TO SUPPORT
RESEARCH EDUCATION AND
COMPLIMENTS OTHER FORMAL
TRAINING PROGRAMS THAT ALREADY
EXIST RELATED TO SUBSTANCE USE
AND SUBSTANCE USE DISORDER
RESEARCH.
THE FOCUS MAY BE ON ANY TOPIC
SUCH AS CLINICAL AND
DIAGNOSTICS, TREATMENT,
PREVENTION, TREATMENT, CLINICAL
NEUROSCIENCE, MEDICAL
CONSEQUENCES OF SUBSTANCE USE,
ANY OF THESE TOPICS ARE FAIR
GAME AS WELL AS HIV RELATED
RESEARCH AND ENCOURAGE MUL
MULTI-DISCIPLINARY RESEARCH AND
HOLD THERE AND SEE IF THERE'S
ANY COMMENTS.
>>ARE THERE ANY QUESTIONS?
>>WE CAN GO TO THE NEXT
CONCEPT.
>>FOR THE DIVISION OF
EPIDEMIOLOGY AND SERVICES AND
PREVENTION RESEARCH THE FIRST IS
A CONTRACT CONCEPT PRESENTED BY
JANET KURAMOTO-CRAWFORD.
>>GOOD AFTERNOON.
I'M PRESENTING THE NATIONAL
ADDICTION AND HIV DATA ARCHIVE
PROGRAM.
IT'S A NIDA FUNDED PROGRAM THAT
PRESERVES DATA RELEVANT TO A
DRUG ADDICTION AND THOSE THAT
INTERSECT WITH HIV RESEARCH
ESTABLISHED IN 2001 BASED ON THE
INCREASED IMPORTANCE OF DATA
SHARING AND HAS MADE OVER 500
AVAILABLE TO REUSE.
SOME HIGHLIGHTED STUDIES ARE THE
MONITORING THE FUTURE STUDY
MENTIONED IN DR. VOLKOW'S REPORT
AND THE POPULATION ASSESSMENT OF
TOBACCO AND HEALTH STUDY.
THEY HAVE PROVIDED END TO END
USES AND THE CONTINUATION OF
THAT IN LIGHT OF THE SHARING
POLICY TO BROADEN THE
REQUIREMENT FOR DATA SHARING FOR
NIH FUNDED PROJECTS.
AND THE GOAL OF THE CONCEPT IS
TO SUPPORT THE CONTINUATION, TO
ARCHIVE DRUG ADDICTION AND
SCIENTIFIC DATA AND THE DATA
THAT INTERSECTIONS WITH HIV
RESEARCH.
FOR THE FOCUS ON BEHAVIORAL
SCIENCE FIELD.
THE SPECIFIC GOALS INCLUDE
MAINTAINING, DEVELOPING AND
EXPANDING THE PROGRAM AND
PROVIDING TECHNICAL ASSISTANCE
TO INVESTIGATORS DEPOSITING THE
DATA AND A SYSTEM IN WHICH TO
PRIORITIZE IN THE ARCHIVE AND
APPLYING TECHNIQUES TO MAKE SURE
THE DATA ARE AVAILABLE IN A SAFE
AND SECURE MANNER AND FACILITATE
SHARING OF THE DATA INCLUDING
SUPPORT AND TECHNICAL ASSISTANCE
AND TRAINING IN THE FIELD.
THANK YOU FOR YOUR TIME AND
ATTENTION.
>>CAN WE GET A VOTE ON IT AND
MOTION TO APPROVE?
>>THANKS.
NEXT WILL BE BY KATHY ETZ
LOOKING AT OPIOID DRUG USE AND
PAIN.
>>THANK YOU FOR HAVING ME.
I'LL TRY TO MOVE QUICKLY BUT THE
BACKGROUND AND JUSTIFICATION FOR
THE CONCEPT IS WE KNOW AMERICAN
INDIAN AND ALASKAN NATIVE
COMMUNITIES BROUGHT INNOVATIONS
TO ADDRESS SUBSTANCE MISUSE BUT
HAVE THE HIGHEST RATES RELATIVE
TO DEATHS COMPARED TO OTHER
GROUPS AND DUE TO TRAUMA AND
STRUCTURAL BARRIERS TO GOOD
HEALTH.
TO THINK WHAT THE NIH COULD DO
TO ADDRESS THESE ISSUES, A
TRIBAL CONSULTATION WAS HELD IN
MARCH WHERE TRIBAL LEADERS WERE
INVITED IN AND SHARED WITH US
WHAT THEY WERE PRIORITIZING IN
THE AREA.
WHAT THEY TOLD US WAS THEY
HIGHLIGHTED RESEARCH GAPS THAT
REQUIRE CULTURAL EXPERTISE AND
KNOWLEDGE OF LOCAL COMMUNITY
CONDITIONS AND INTEGRATING
TRADITIONAL MEDICINE AND
CEREMONY AND SPIRITUALITY AND
LOOKING AT THE CAUSES OF SOCIAL
DETERMINATES OF HEALTH AND SO
SOMETHING WE HEARD OVER AND OVER
IS THE NEED TO SUPPORT TRIBES
THEMSELVES AND/OR AMERICAN
CANADIAN, ALASKAN NATIVE
POPULATIONS AND BUILDING AND
ENHANCING RESEARCH CAPACITY AND
INFRASTRUCTURE AND FINALLY
SOMETHING MELISSA BROUGHT UP
TODAY, THIS GRATE NEED FOR
IMPROVED DATA TO SUPPORT
COMMUNITY RESPONSE.
THE GOALS OF THE PROGRAM AS
WE'RE CALLING IT ARE TO DIRECTLY
RESPOND IT IN TRIBAL
CONSULTATION BY DEVELOPING AN
INNOVATIVE AND AGILE PROGRAM
FOUNDED ON TRIBAL SOVEREIGNTY
AND ARE REALIZE ON THE DEEP
ENGAGEMENT INCORPORATING
INDIGENOUS KNOWLEDGE, ETCETERA.
WE'RE THINKING ABOUT THIS
PROGRAM AS SOMETHING THAT WILL
BE FLEXIBLE AND WE'LL BE ABLE TO
ADAPT AS NEW SOLUTIONS EMERGE IN
REAL TIME.
THE GOALS OF THE PROGRAM ARE TO
SUPPORT TRIBES AND AMERICAN
INDIAN AND ALASKAN NATIVE
POPULATIONS TO IMPROVE THE DATA
AND RESEARCH AND LOOK AT FACTORS
RELATED TO DRUG MISUSE AND
OVERDOSE AND EXPAND RESEARCH
CAPACITY AND INFRASTRUCTURE TO
PROVIDE COMPREHENSIVE AND
ONGOING TECHNICAL ASSISTANCE AND
TO DEVELOP AND IMPLEMENT BEST
PRACTICES FOR SHARING PRINCIPLES
AND SOVEREIGNTY.
THANK YOU FOR YOUR TIME.
>>CAN I GET A MOTION TO APPROVE
IT?
ANY COMMENTS OR QUESTIONS?
NOT HEARING ANYTHING, CAN I GET
A MOTION TO APPROVE?
NOW THE OTHER CONCEPTS.
THIS SAY OF THEM AND THESE ARE
UST BEING PRESENTED FOR GENERAL
FEEDBACK.
PLEASE STOP IF YOU WANT TO ASK
QUESTIONS BUT I'LL TURN IT OVER.
SHE'S GOT EIGHT TO DO.
>>SEVEN, I BELIEVE.
I'M MEDICAL OFFICER IN THE
MEDICAL SERVICES BRANCH AND I'M
FIRST IS ENDING THE EPIDEMIC,
NEW MODELS OF INTEGRATED
HIV/AIDS ADDICTION AND PRIMARY
CARE SERVICES SUPPORTING THE NEW
MODELS OF CARE THAT FUNCTION AS
ONE STOP SHOPS CAPABLE OF
INTEGRATING SERVICES INCLUDING
HIV/AIDS AND ADDICTION AND
PRIMARY CARE SERVICES.
IT EXPANDS THE SCOPE TO INCLUDE
HEPATITIS B AND C AND RE-STRICKS
INTERNATIONAL SETTINGS TO LOW
AND MIDDLE INCOME COUNTRIES.
THE SECOND IS ENGAGING SURVIVORS
OF SEXUAL VIOLENCE AND
TRAFFICKING IN HIV AND SUBSTANCE
USE DISORDER SERVICES.
THIS IS ALSO LED BY MINNJUAN FOR
INTERVENTIONS TO ADDRESS THE
INTERRELATED AND COMPOUNDING
CONTEXTUAL FACTORS THAT
CONTRIBUTE TO FACTORS AND BUILD
NEW INTERVENTIONS AND MODELS OF
CARE TO ENGAGE SEXUAL
TRAFFICKING SURVIVORS IN CARE
FOR SUBSTANCE USE DISORDER, HIV,
TRAUMA AND OTHER MENTAL HEALTH
OUTCOMES AND ADDRESS KEY
STRUCTURAL AND SOCIAL
DETERMINATES OF HEALTH THAT
CONTRIBUTE TO RISK FOR SEXUAL
TRAFFICS AND BARRIERS TO AND
FACILITATING OF ESCAPE OF
CONTINUED EXPLOITATION.
THE THIRD IS ADDRESSING HIV IN
THE HIGHEST RISK SEXUAL AND
GENDER MINORITIES LED BY RICHARD
JENKINS.
IT LOOKS TO ADDRESS THE
PROPORTIONS OF HIV CASES IN
GENDER AND ETHNIC MINORITIES.
IT WILL SUPPORT EPIDEMIOLOGIC
RESEARCH AND LOOKING AT
COMORBIDITIES SUCH AS SEXUALLY
TRANSMITTED INFECTIONS AND
HEPATITIS C AND PSYCHIATRIC
DISORDERS.
IT WILL INCLUDE INCLUSION OF END
USERS OF RESEARCH FINDINGS AND
SOCIAL DETERMINATES OF HEALTH
WITH HIV AND PROBLEMATIC
SUBSTANCE USE.
THE FOURTH CONCEPT IS COHORT
STUDIES OF HIV/AIDS AND
SUBSTANCE USE LED BY SHEBA
DUNSTON AND CONTINUE ADDRESSING
HIGH-PRIORITY RESEARCH ON
MULTI-DISCIPLINARY ASPECTS OF
HIV/AIDS AND SUBSTANCE USE IN
ALIGNMENT WITH NIH PRIORITIES.
TO ALIGN SYSTEM LEVEL OR
MULTILEVEL HIV PREVENTIONS FOR
TESTING AND DIAGNOSIS AND
TREATMENT AS WELL AS INFORM
IMPLEMENTATION RESEARCH IN
SUBSTANCE USE AND HIV
PREVENTION, SCREENING, TREATMENT
AND MEDICAL CARE.
-- BEFORE YOU GO ONP, ARE THERE
COMMENTS OR QUESTIONS?
>>SURE, SINCE THIS IS THE HIV
GROUP?
>>WE CAN MOVE ON.
>>OUR FIFTH CONCEPT IS RESEARCH
TO ADDRESS SUD IN CRIMINAL-LEGAL
SYSTEM.
IT BUILDS ON THE HISTORY OF
CONDUCTING SERVICES RESEARCH TO
ADDRESS SUBSTANCE USE DISORDER
AMONG INDIVIDUALS INVOLVED IN
THE CRIMINAL LEGAL SYSTEM.
IT SEEKS TO BUILD ON PAST
INITIATIVES TO TAKE EFFECTIVE
INTERVENTIONS TO SCALE IN JAILS,
COURTS AND COMMUNITY CORRECTIONS
AND ADDRESSING THE COMPLEX NEEDS
OF INDIVIDUALS WITH SUBSTANCE
USE DISORDERS AT EARLIER POINTS.
THE SIXTH IS RESEARCH TO
INCREASE IMPLEMENTATION OF
SUBSTANCE USE PREVENTION
SERVICES LED BY NAMY GOLDSTEIN.
IT WILL BE PART OF THE HEAL
RESEARCH PROGRAM AND ADDRESSES
EXISTING GAPS TO IDENTIFY
EFFECTIVE STRATEGIES TO
DISSEMINATE AND SUPPORT THE
CREATION AND STRENGTHEN OF A
PREVENTION INFRASTRUCTURE.
EXAMPLE AREAS OF INTEREST
INCLUDE SCIENTIFIC SOLUTIONS TO
WORKFORCE CAPACITY CHALLENGE,
RESEARCH TO LEVEL TECHNOLOGY TO
FACILITATE ACCESS TO PREVENTIVE
CARE AND STUDIES OF STRATEGIES
TO IMPACT ORGANIZATIONAL
STRUCT
STRUCTURE, CLIMBATE AND
STRUCTURE AND LOOK AT SERVICES.
THE SEVEN AND FINAL SERVICES IS
RESOURCE NETWORKS TO ADVANCE THE
ADDICTION OF RESOURCES RESEARCH
THROUGH RESEARCHER DECISION
MAKER COLLABORATIONS.
IT BY SARAH DUFFY.
IT WOULD LOOK AT MULTI-DECISION
NETWORKS IN ENHANCING THE
QUALITY AND EFFECTIVENESS OF
ADDICTION TREATMENT AND FOCUS ON
THE TIMELY GENERATION,
DISSEMINATION AND APPLICATION OF
RELEVANT RESEARCH FINDINGS IN
REAL-WORLD SETTINGS.
THOSE ARE ALL OF OUR CONCEPTS
AND WE'RE HAPPY TO TAKE
ADDITIONAL QUESTIONS.
>>NEXT TO DTNC, TANYA RAMIE.
>>HI, EVERYONE.
THANK YOU FOR GIVING ME THE
OPPORTUNITY TO PRESENT THIS
CONCEPT.
THIS IS THE DEVELOPMENT OF
CLINICAL OUTCOME ASSESSMENTS AS
NEW FDA-QUALIFIED DRUG
DEVELOPMENT TOOLS FOR OPIOID AND
STIMULANT USE DISORDERS TO AC
ACCELERATE THERAPEUTIC
DEVELOPMENT.
I'LL TALK ABOUT THIS CONCEPT.
THE CONCEPT WAS PUT TOGETHER IN
ORDER TO ACCELERATE THE
DEVELOPMENT OF NEW THERAPEUTICS
FOR OPIOID USE DISORDER AND
STIMULANT USE DISORDER.
THERE'S A NEED TO LOOK AT
CLINICAL OUTCOME ASSESSMENTS.
THAT WILL NEED THE DRUG
DEVELOPMENT TOOL QUALIFICATION
FROM THE FDA.
THERE'S A PROCESS WHICH IS
EMBEDDED IN THE REQUIREMENTS.
AND THERE'S A GUIDANCE RELATED
TO THAT.
CURRENTLY WE DON'T HAVE IN THE
ADDICTION FIELD THE FDA
QUALIFIER AND OUTCOME ASSES
ASSESSMENTS BEING CONSIDERED TO
BE DRUG DEVELOPMENT TOOLS.
WHY IS THIS IMPORTANT?
BECAUSE IT WOULD SPEED UP THE
REGULATORY REVIEW PROCESS AS
THERE WILL BE NO ASSESSMENTS
NEEDED TO ESTABLISH THE CLINICAL
OUTCOMES ASSESSMENTS IN EACH AND
EVERY DRUG DEVELOPMENT PROGRAM
THAT HAS ADDICTION END POINTS.
THIS IS TO SUPPORT THE
DEVELOPMENT OF THE CLINICAL
OUTCOME ASSESSMENTS FOR OPIOID
AND STIMULANT USE DISORDERS AND
FOLLOW THE FDA QUALIFICATION
PATHWAY OUTLINED WITH SPECIFIC
GUIDANCE.
>>WE DON'T DISCUSS THE
MECHANISMS.
IT'S JUST THE SCIENTIFIC CONCEPT
WHICH YOU LAID OUT VERY WELL.
>>THANK YOU VERY MUCH.
ALSO NOTE IT ALIGNS WITH THE
HEAL GOALS AND MISSION.
>>DID YOU HAVE A COMMENT?
>>I DID.
I WAS WONDERING IF THIS IS
DESPERATELY NED EDED AND WOULD
APPLY FOR POLY SUBSTANCE USE
DISORDER?
IT GETS COMPOUNDED THERE AND
OPIOID AND STIMULANT USE IS
COMBINED WITH OTHER SUBSTANCES.
I KNOW THAT'S A NIDA PRIORITY
BUT IT BECOMES A BIGGER ISSUE
WHEN WE START TO THINK OF
TREATMENT DEVELOPMENT IN PSUD
ANA.
>>YES.
VERY GOOD QUESTION.
THE DRUG DEVELOPMENT PROCESS IS
RIGOROUS.
IT TAKES TIME AND A TEAM WITH
FDA TO REVIEW THE PLAN,
ETCETERA.
THIS FOR US IS ONLY THE
BEGINNING.
WE WILL CERTAINLY CONTINUE AND
THE FUTURE GOAL TO BE ABLE TO
INCLUDE THE POLY SUBSTANCE USE
DISORDER RELEVANT END POINTS TOO
THE PROCESS THAT WOULD BE A HUGE
ACCOMPLISHMENT.
WE ARE GOING TO START FROM WHAT
IS SEEN AS KEY AND CURRENT OUD
AND STIMULANT USE DISORDERS AND
WE HOPE WE'LL BE ABLE TO HAVE
THE QUALIFICATION WITH TO THE
FIRST BUT WILL CONSIDER POLY
SUBSTANCE ONCE WE PUT OUR FOOT
IN THE DOOR.
>>THANK YOU VERY MUCH.
SORRY TO BE CUTTING YOU OFF BUT
I'M WORRIED ABOUT TIME.
WE'RE SUPPOSED TO BE FINISHED IN
TWO MINUTES AND HAVE ALL DNB AND
ENERGY CONTRACT.
UNLESS THERE'S ANY CONCERNS OR
OBJECTS I THINK WE SHOULD MOVE
ON TO DNB.
>>OKAY.
DA-YU.
>>THANK YOU.
GOOD AFTERNOON.
DNB HAS 10 CONCEPTS.
I'LL MAKE IT VERY BRIEF.
ONE, EX VIVO MODELS FOR THE
STUDY OF HIV AND POLY SUBSTANCE
USE.
THIS IS ELUCIDATING IMMUNE AND
PATHOPHYSIOLOGY USING EX VIVO
PLATFORMS FROM HUMAN INDUCED
PLURIPOTENT CELLS.
TWO, MECHANISM STUDIES ON THE
EFFECTS OF FIEZO SOCIAL STRESS
IN COMPLEX MORBIDITY INVOLVING
SUDs, PSYCHIATRIC DISORDERS AND
HIV.
THIS IS TO SUPPORT HUMAN
SUBJECTS AND ANIMAL MODEL
RESEARCH AIMING TO ELUCIDATE THE
NEUROCOGNITIVE AND
NEUROBIOLOGICAL MECHANISMS THAT
UNDER LIE THE ASSOCIATIONS
BETWEEN PSYCHOSOCIAL STRESS AND
SUDs, PSYCHIATRIC DISORDERS AND
HIV RELATED CNS PATHOLOGY.
THREE, EFFECTS OF HIV AND
SUBSTANCE USE COMORBIDITY ON THE
PLACENTA, ALSO BY SUNILA NAIR.
THIS IS TO TARGET THE
UNDERSTANDING OF THE EFFECTS OF
HIV ON THE GROWTH, DEVELOPMENT
AND FUNCTIONING OF THE PLACENTA
IN PREGNANT INDIVIDUALS WITH
SUBSTANCE USE, MISUSE AND THE
UNDERLYING MECHANISMS AND THE
IMPACT OF A PLACENTAL
ABNORMALITIES ON MATERNAL FETAL
AND OTHER NEONATAL OUTCOMES.
FOUR, INTERPLAY OF AUTOPHAGY
RELATED CELL DEATH AND HIV
PATHOGENESIS IN SUBSTANCE USE
DISORDERS BY ANNE TSAI.
FOCUSSING ON THE IMMUNE
RESPONSES OF SUBSTANCE USE IN
HIV DISEASE PROGRESSION WITH A
FOCUS ON THE INTERPLAY OF
AUTOPHAGY AND HIV IN EARLY
INFECTION AND REPLICATION.
FIVE, TARGETING INFLAMASOMES IN
HIV BY ANNE TSAI.
TO INVESTIGATE THE UNDERLYING
MECHANISMS IN CNS SEQUENCES OF
MYELOID CELL TRIGGERED IN
FLAMAS
FLAMASOME AND SUBSTANCE USE.
ANY QUESTIONS FOR THE FIRST
FIVE?
>>PLEASE GO AHEAD.
>>SIX, RESEARCH ON THE
NEUROIMMUNE AXIS IN THE CONTEXT
OF HIV AND SUBSTANCE USE.
THIS IS BY KIRA VEMURI.
TO ENCOURAGE RESEARCH FOR
IDENTIFYING BIOLOGICAL TARGETS
AND PATHWAYS THAT REGULATE
NEUROIMMUNE INTERACTIONS THAT
ARE AT THE INTERSECTION OF HIV
AND SUBSTANCE USE.
IT ALSO ENCOURAGES THE RESEARCH
TOWARDS THE DISCOVERY OF NOVEL
CHEMICAL ENTITIES THAT ARE
EFFECTIVE IN MITIGATING
CONDITIONS ASSOCIATED WITH HIV
AND SUBSTANCE USE INCLUDING HIV
ASSOCIATED NEUROCOGNITIVE
DISORDER, PAIN AND AGING.
SEVEN, CHEMICAL PROBES AND DRUGS
FOR MODULATING HIV TRANSCRIPTION
IN PEOPLE WITH SUBSTANCE USE
DISORDERS.
BY SAM ANATHAN.
THE FIRST IS TO IDENTIFICATION
OF TARGETS AND PANEL WAYS BY
WHICH TRANSCRIPTIONAL ACTIVITY
OF HIV CAN BE EXPRESSED IN HIV
RESERVOIRS INCLUDING PEOPLE WITH
SUD AND THE SECOND ONE IS
APPLICATION OF EMERGING SMALL
MOLECULE DRUG DISCOVERY
APPROACHES TO IDENTIFY NOVEL
COMPOUNDS THAT CAN BE UTILIZED
AS PHARMACOLOGIC PROBES AND AS
DRUGS TO SUPPRESS HIV
TRANSCRIPTION IN PEOPLE WITH
HIV, SUD, COMORBIDITY.
EIGHT, MICROGLIAL
PATHOPHYSIOLOGY IN HIV AND SUD
BY TRISTAN McCLURE-BEGLEY.
TO IDENTIFY MICROGLIAL PROTEIN
TYPES AND EMPHASIZING THE
MICROGLIAL PROTEIN EXPRESSION
AND POST TRANSLATIONAL
MODIFICATIONS IN THE BRAIN
REGIONS IN THE CONTEXT OF EACH
CONDITIONS ALONE OR WHEN
PRESENTED TOGETHER.
NINE, SCORCH.
SINGLE CELL OPIOID RESPONSES IN
THE CONTEXT OF HIV PROGRAM.
THIS IS FOR DATA COORDINATION,
ANALYSIS AND SCIENTIFIC OUTREACH
BY JOHN SATTERLEE.
AMONG OTHER THINGS THIS CONCEPT
SEEMS TO INGEST ADDITIONAL DATA
SETS FROM SCORCH DATA GENERATION
PROJECTS LINK THE MOLECULAR DATA
WITH APPROPRIATE METADATA
INCLUDING CLINICAL METADATA FROM
NATIONAL HIV TISSUE CONSORTIUM
AND OTHER BRAIN BANKS AND
SOURCES.
TEN, SCORCH, SINGLE CELL OPIOID
RESPONSES IN THE CONTEXT OF HIV
PROGRAM.
THIS IS FOR DATA MINING AND
FUNCTIONAL VALIDATION ALSO BY
JOHN SATTERLEE.
THE AIM IS TO IDENTIFY CELL
TYPES TRANSCRIPTS, ENHANCERS OR
TRANSCRIPTIONAL NETWORKS THAT
PLAY A ROLE IN HIV ARC OR SUD
MOLECULAR RESPONSES.
IT SUPPORTS FUNCTIONAL
VALIDATION STUDIES TO CONFIRM OR
DENY A BIOLOGICAL ROLE FOR DATA
MINED CELL TYPES, TRANSCRIPTS,
ENHANCERS OR TRANSCRIPTIONAL
NETWORKS IN HIV ART OR MOLECULAR
RESPONSES.
THESE ARE THE OTHER FIVE AND IF
YOU HAVE ANY QUESTIONS?
>>I'M NOT SEEING HANDS RAISED.
>>THEN I'M DONE.
>>THIS IS THE LAST CONCEPT FOR
A CONTRACT AND SO WE'LL NEED IT
GET A VOTE FROM YOU ON THIS AND
ELIZABETH HOFFMAN WILL BE
PRESENTING THIS.
>>I'LL BE QUICK.
THIS IS A CONCEPT TO SUPPORT
DATA SHARING PLATFORM FOR THE
ABCD STUDY.
AS YOU KNOW THE ABCD STUDY HAD
DATA BROADLY AVAILABLE TO THE
SCIENTIFIC COMMUNITY SINCE 2018.
THE DATA SET INCLUDES A VARIETY
OF DATA FROM DATA AND TO DATE
APPROXIMATELY 500 PAPERS HAVE
BEEN PUBLISHED USING THE DATA.
AS THE DATA COLLECTION HAS
PROGRESSED, THE AMOUNT AND TIMES
OF COMPLEXITY OF THE DATA HAVE
SIGNIFICANTLY INCREASED AND WILL
CONTINUE TO DO SO THROUGH THE
LIFE CYCLE OF THE STUDY AND THE
NICE OF THE COMMUNITY EVOLVED
WHERE AN ANALYTIC PLATFORM IS
CRITICAL TO FACILITATE THE USE
OF THE DATA FROM DIFFERENT
SCIENTISTS FROM DIFFERENT
BACKGROUNDS AND DIFFERENT LEVELS
OF EXPERTISE AND TRAINING.
THE CURRENT PLATFORM CAN NO
LONGER MEET THE NEEDS OR SCALE
AS THE DATA SET CONTINUES TO
GROW.
WHAT WE'RE LOOKING FOR IS A DATA
SHARING PLATFORM OPTIMIZED FOR
GENOMICS AND OTHER COMPLEX DATA
AND FLEXIBLE BY DESIGN.
PLATFORM ALSO MUST PROVIDE
MULTIPLE WAYS TO ACCESS AND
ANALYZE THE DATA AND SUPPORTING
A PLATFORM THAT'S WELL SUITED TO
SHARING MYRIAD COMPLEX DATA
TYPES INCLUDING NEUROIMAGING AND
GENOMICS AND INTEGRATED DATA
ANALYSIS TO ENSURE THE STUDIES
CONTINUITY FOR THE FUTURE AS
WELL AS A HOMOGENOUS SOLUTION
FOR PLANNED DATA FROM THE
HEALTHY BRAIN AND CHILD STUDY.
THANKS.
>>ANY COMMENTS OR QUESTIONS
BEFORE WE TAKE A VOTE?
>>I HAVE A QUICK QUESTION.
IS THIS A CONTRACT?
>>YES, IT IS A CONTRACT.
THAT'S WHY WE NEED A VOTE.
>>GOT IT.
>>ANY OTHER QUESTIONS.
-- ANY OTHER QUESTIONS?
MOTION TO AAPPRPPRAPPROVE?
SECOND.
ANYBODY DISAPPROVE?
THANK YOU ALL VERY MUCH.
ANNAROSE YOU HAD A QUESTION?
>>NOPE, JUST TRYING TO GET MY
HAND DOWN.
>>DENNIS, DID YOU HAVE A
QUESTION?
>>NO, JUST FOR MY VOTE.
OKAY.
THANKS VERY MUCH, ELIZABETH.
THE LAST PART OF THIS IS
SUPPOSED TO BE PUBLIC COMMENTS.
WE DID NOT RECEIVE ANY COMMENTS
AHEAD OF TIME.
IF THERE ARE PEOPLE WHO ARE
WATCHING THIS AND WANT TO SEND
COMMENTS, YOU HAVE 10 DAYS FROM
TODAY TO SEND COMMENTS WHICH WE
WILL READ AND CONSIDER.
I WILL TURN IT BACK OVER TO NORA
TO THANK YOU ALL AND BID YOU
FAREWELL.
GO AHEAD, NORA.
>>I WANTED TO THANK ALL THE
COUNCIL MEMBERS FOR ALL THEIR
INPUT AND GREAT PRESENTATIONS
MADE BY EVERYONE.
AND THANK YOU, SUSAN AND KATHY
FOR MAKING THIS POSSIBLE.
I HOPE AS WE GO ALONG THERE WILL
BE AN OPPORTUNITY TO GET
TOGETHER IN A REAL PLACE AND
DISCUSS.
SOMETIMES I FEEL THERE'S ISSUES
THAT COME ABOUT.
WE RELIED ULTIMATELY ON YOUR
INPUT AND WARE REPRESENTING
CONCEPTS BASICALLY THESE ARE
DRIVEN BY MULTIPLE SOURCES BUT
WANT TO BE CERTAIN COUNCIL IS
INVOLVED WITH THEM.
WHETHER WE ARE IN CONSULT
OFFICIALLY OR NOT REACH OUT IF
YOU HAVE SUGGESTIONS HOW TO MOVE
FORWARD.
AGAIN, THANKS VERY MUCH FOR ALL
YOUR PARTICIPATION AND WORK TO
ENSURE THE SCIENCE OF NIDA IS AS
RIGOROUS AND IMPACTFUL AND
EQUITABLE AS POSSIBLE.
THANKS VERY MUCH AND I WISH YOU
I NICE DAY.
>>AND OUR PLAN SO FAR IS TO
HAVE THE NEXT COUNCIL MEETING IN
PERSON OR HYBRID IN MAY AND
THAT'S THE TWO-DAY MEETING.
WE HOPE WE WILL BE ABLE TO SEE
YOU ALL.
THANKS SO MUCH FOR ALL OF YOUR
TIME AND FOR YOUR VERY HELPFUL
INPUT.
>>GOOD-BYE, EVERYONE.